<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">AIDS Behav</journal-id><journal-id journal-id-type="iso-abbrev">AIDS Behav</journal-id><journal-id journal-id-type="pmc-domain-id">365</journal-id><journal-id journal-id-type="pmc-domain">springeropen</journal-id><journal-title-group><journal-title>AIDS and Behavior</journal-title></journal-title-group><issn pub-type="ppub">1090-7165</issn><issn pub-type="epub">1573-3254</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Springer</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC11586311</article-id><article-id pub-id-type="pmcid-ver">PMC11586311.1</article-id><article-id pub-id-type="pmcaid">11586311</article-id><article-id pub-id-type="pmcaiid">11586311</article-id><article-id pub-id-type="pmid">39264485</article-id><article-id pub-id-type="doi">10.1007/s10461-024-04494-w</article-id><article-id pub-id-type="publisher-id">4494</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Original Paper</subject></subj-group></article-categories><title-group><article-title>Pain, Substance Use Disorders, Mental Health, and Buprenorphine Treatment among Patients With and Without HIV</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Miller</surname><given-names initials="EA">Emily A.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>McGinnis</surname><given-names initials="KA">Kathleen A.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Edelman</surname><given-names initials="EJ">E. Jennifer</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Feinberg</surname><given-names initials="T">Termeh</given-names></name><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gordon</surname><given-names initials="KS">Kirsha S.</given-names></name><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Kerns</surname><given-names initials="RD">Robert D.</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Marshall</surname><given-names initials="BDL">Brandon D. L.</given-names></name><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Patterson</surname><given-names initials="JA">Julie A.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-1408-0868</contrib-id><name name-style="western"><surname>McRae</surname><given-names initials="M">MaryPeace</given-names></name><address><email>mpmcrae@vcu.edu</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff9">9</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02nkdxk79</institution-id><institution-id institution-id-type="GRID">grid.224260.0</institution-id><institution-id institution-id-type="ISNI">0000 0004 0458 8737</institution-id><institution>Department of Pharmacotherapy and Outcomes Science, </institution><institution>Virginia Commonwealth University School of Pharmacy, </institution></institution-wrap>Richmond, VA USA </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/000rgm762</institution-id><institution-id institution-id-type="GRID">grid.281208.1</institution-id><institution-id institution-id-type="ISNI">0000 0004 0419 3073</institution-id><institution>VA Connecticut Healthcare System, </institution></institution-wrap>West Haven, CT USA </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03v76x132</institution-id><institution-id institution-id-type="GRID">grid.47100.32</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8710</institution-id><institution>Section of General Internal Medicine, </institution><institution>Yale University School of Medicine, </institution></institution-wrap>New Haven, CT USA </aff><aff id="Aff4"><label>4</label>Kelly Government Solutions, Silver Spring, MD USA </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.47100.32</institution-id><institution-id institution-id-type="ISNI">0000000419368710</institution-id><institution>Department of Biostatistics, </institution><institution>Yale University School of Public Health, </institution></institution-wrap>New Haven, CT USA </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/03v76x132</institution-id><institution-id institution-id-type="GRID">grid.47100.32</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 8710</institution-id><institution>Center for Medical Informatics, </institution><institution>Yale University School of Medicine, </institution></institution-wrap>New Haven, CT USA </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="GRID">grid.47100.32</institution-id><institution-id institution-id-type="ISNI">0000000419368710</institution-id><institution>Department of Psychiatry, </institution><institution>Yale University School of Medicine, </institution></institution-wrap>300 George Street, Suite 901, New Haven, CT USA </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="GRID">grid.40263.33</institution-id><institution-id institution-id-type="ISNI">0000 0004 1936 9094</institution-id><institution>Department of Epidemiology, </institution><institution>Brown University School of Public Health, </institution></institution-wrap>Providence, RI USA </aff><aff id="Aff9"><label>9</label>410 North 12th Street, Richmond, VA 23298 USA </aff></contrib-group><pub-date pub-type="epub"><day>12</day><month>9</month><year>2024</year></pub-date><pub-date pub-type="ppub"><year>2024</year></pub-date><volume>28</volume><issue>12</issue><issue-id pub-id-type="pmc-issue-id">475679</issue-id><fpage>3994</fpage><lpage>4004</lpage><history><date date-type="accepted"><day>29</day><month>8</month><year>2024</year></date></history><pub-history><event event-type="pmc-release"><date><day>12</day><month>09</month><year>2024</year></date></event><event event-type="pmc-live"><date><day>26</day><month>11</month><year>2024</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-11-26 00:25:44.637"><day>26</day><month>11</month><year>2024</year></date></event><event event-type="pmc-version" specific-use="live"><article-id pub-id-type="pmcaiid">11586311</article-id><article-id pub-id-type="doi">10.1007/s10461-024-04494-w</article-id><article-version>1</article-version><pub-date><day>12</day><month>09</month><year>2024</year></pub-date></event><event event-type="pmc-version" specific-use="live"><article-id pub-id-type="pmcaiid">11588514</article-id><article-id pub-id-type="doi">10.1007/s10461-024-04494-w</article-id><article-id pub-id-type="manuscript-id">NIHMS2035331</article-id><article-version>2</article-version><pub-date><day>12</day><month>09</month><year>2024</year></pub-date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#8217;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#8217;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="10461_2024_Article_4494.pdf"/><abstract id="Abs1"><p id="Par1">Treatment of opioid use disorder (OUD) with buprenorphine improves outcomes and mortality among people with HIV (PWH). However, engagement is low and is influenced by comorbidities. We examined the impact of patterns of co-occurring pain, substance use disorders (SUDs), and mental health diagnoses on buprenorphine initiation and retention in PWH. The Veterans Aging Cohort Study contained 7,875 patients (2,702 PWH and 5,173 without HIV) with new OUD clinical encounters (2008&#8211;2017). Buprenorphine initiation and retention were derived from prescription data. We identified patterns of co-occurring diagnoses (via ICD codes) and assessed the effects of class membership on both outcomes using latent class analysis and regression analyses. The mean age of patients was 55, 98% were male, 58% Black, 8% Hispanic, and only 8% initiated buprenorphine within 12 months of OUD diagnosis. Four classes of co-occurring diagnoses were identified: &#8220;Few Co-occurring Diagnoses&#8221; (42.3%); &#8220;Multiple Pain Conditions&#8221; (21.3%); &#8220;Pain&#8201;+&#8201;SUD&#8221; (18.4%) and &#8220;Pain&#8201;+&#8201;SUD&#8201;+&#8201;Mental Health&#8221; (18.0%). Patients in the &#8220;Pain&#8201;+&#8201;SUD&#8221; class and &#8220;Pain&#8201;+&#8201;SUD&#8201;+&#8201;Mental Health&#8221; class were significantly less likely to initiate buprenorphine and had 59% and 45% lower odds, respectively, of initiating buprenorphine compared with patients in the &#8220;Few Co-occurring Diagnoses&#8221; class; this effect did not vary by HIV status. Buprenorphine retention was not significantly associated with HIV status or class membership. However, Black Veterans were less likely to initiate or be retained in buprenorphine treatment. Higher comorbidity burden was negatively associated with buprenorphine initiation but not with retention. More research is warranted to determine other factors that may influence treatment retention.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>HIV</kwd><kwd>Opioid use disorder</kwd><kwd>Population analysis</kwd><kwd>Buprenorphine</kwd><kwd>Veterans</kwd><kwd>Mental health</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000027</institution-id><institution>National Institute on Alcohol Abuse and Alcoholism</institution></institution-wrap></funding-source><award-id>U10AA013566</award-id><award-id>U24 AA020794</award-id><award-id>U01 AA020790</award-id></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000026</institution-id><institution>National Institute on Drug Abuse</institution></institution-wrap></funding-source><award-id>R01 DA053153</award-id><principal-award-recipient><name name-style="western"><surname>McRae</surname><given-names>MaryPeace</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Science+Business Media, LLC, part of Springer Nature 2024</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par4">The rate of opioid use disorder (OUD) is 2&#8211;4 times higher among persons with human immunodeficiency virus (PWH) compared to the national average [<xref ref-type="bibr" rid="CR1">1</xref>&#8211;<xref ref-type="bibr" rid="CR4">4</xref>]. Specifically, nationally representative estimates suggest that as many as 24,000&#8211;48,000 PWH in the United States meet the criteria for a current OUD diagnosis. Opioid agonist therapy includes buprenorphine and methadone. Both medications are effective at reducing opioid cravings, opioid use, related overdose and mortality [<xref ref-type="bibr" rid="CR5">5</xref>]. Additionally, treatment of OUD improves HIV-related outcomes, such as antiretroviral receipt and adherence as well as HIV viral suppression [<xref ref-type="bibr" rid="CR6">6</xref>]. However, despite the effectiveness of opioid agonist therapy, engagement with opioid agonist therapy remains low among both PWH and persons without HIV (PWoH) [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>].</p><p id="Par5">Numerous studies have described predictors of opioid agonist therapy initiation and retention among PWH and PWoH. Previous research suggests that some co-occurring mental health conditions, including bipolar disorder and depression, may be associated with reduced buprenorphine initiation and retention [<xref ref-type="bibr" rid="CR9">9</xref>&#8211;<xref ref-type="bibr" rid="CR11">11</xref>], while post-traumatic stress disorder and anxiety disorder may have no impact on treatment engagement [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. When the impact of co-occurring mental health conditions on OUD treatment engagement have been analyzed collectively (i.e., &#8220;any mental health conditions&#8221;), researchers have reported mixed effects, including decreased, increased, and no change in treatment engagement when considering mental health status [<xref ref-type="bibr" rid="CR14">14</xref>&#8211;<xref ref-type="bibr" rid="CR16">16</xref>]. Conflicting literature on the impact of non-opioid substance use disorders (SUDs), such as alcohol, cocaine, and cannabis use, on engagement in treatment for OUD has reported mixed findings regarding the effect of these co-occurring SUDs on initiation and retention [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. Finally, the role of pain on OUD treatment engagement has not been fully explored. Theoretically, pain may increase opioid craving [<xref ref-type="bibr" rid="CR17">17</xref>], which, in turn, may increase the likelihood of OUD treatment discontinuation [<xref ref-type="bibr" rid="CR18">18</xref>]. However, the observed effect of co-occurring pain diagnoses on treatment engagement is variable, with the presence of co-occurring pain diagnoses reducing the likelihood of buprenorphine initiation [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>] but not retention in treatment [<xref ref-type="bibr" rid="CR16">16</xref>].</p><p id="Par6">The conflicting literature on the effects of co-occurring pain, non-opioid SUDs, and mental health diagnoses, on treatment retention may reflect the complexities of the comorbidities individually or in combination [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR19">19</xref>&#8211;<xref ref-type="bibr" rid="CR23">23</xref>]. Previous studies regarding SUDs have provided insight into substance use and SUD treatment by considering patient characteristics collectively [<xref ref-type="bibr" rid="CR24">24</xref>&#8211;<xref ref-type="bibr" rid="CR27">27</xref>]. Latent class analyses (LCA), which identify subgroups based on patterns of patient characteristics, have been used to investigate how patterns of pain, co-occurring substance use, and mental health diagnoses impact HIV medication adherence [<xref ref-type="bibr" rid="CR28">28</xref>], social functioning [<xref ref-type="bibr" rid="CR29">29</xref>], and health status [<xref ref-type="bibr" rid="CR30">30</xref>]. However, LCA has not been widely used to help explain how patterns of these co-occurring conditions might impact either OUD treatment engagement or retention [<xref ref-type="bibr" rid="CR31">31</xref>].</p><p id="Par7">The objective of this research was to holistically examine the impact of co-occurring pain, SUDs, and mental health diagnoses on buprenorphine treatment engagement among patients with OUD. Specifically, we aimed to: (1) identify patterns of co-occurring pain, SUD diagnoses, and mental health conditions, among patients with OUD with and without HIV; (2) assess whether patterns of co-occurring diagnoses were associated with OUD treatment initiation and engagement; and (3) examine whether the relationship between patterns of co-occurring diagnoses and treatment engagement varied by HIV status.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Materials and Methods</title><sec id="Sec3"><title>Data and Analytic Sample</title><p id="Par8">Electronic medical record data were obtained from the Veterans Aging Cohort Study (VACS), an observational cohort study of PWH (<italic toggle="yes">n</italic>&#8201;=&#8201;55,984) and 1:2 matched PWoH (<italic toggle="yes">n</italic>&#8201;=&#8201;116,705) receiving care at the Veterans Health Administration (VHA) from October 1996 to September 2017 [<xref ref-type="bibr" rid="CR32">32</xref>]. Ascertainment of HIV status and matching in the cohort has been described elsewhere [<xref ref-type="bibr" rid="CR14">14</xref>]. Within VACS, we identified patients with one or more new OUD clinical encounters from January 2008 to September 2017. An OUD behavioral treatment encounter was defined as an inpatient or outpatient encounter with a primary or secondary OUD diagnosis (ICD-9-CM codes 304.0x, 305.5x and 304.7x; ICD-10 codes F11.1x and F11.2x) [<xref ref-type="bibr" rid="CR14">14</xref>]. We considered encounters to be &#8220;new&#8221; treatment episodes if the encounter was preceded by a one year period without opioid agonist therapy or an ICD code for OUD [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR33">33</xref>]. January 2008 was selected as the earliest encounter date because access to buprenorphine was broadly expanded within the VHA system at that time [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. Although methadone and naltrexone are also utilized for OUD, by 2017 the majority of Veterans that were receiving medications for the treatment of OUD (as many as 72%) were treated with buprenorphine [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>].</p></sec><sec id="Sec4"><title>Measures and Patient Characteristics</title><p id="Par9">We examined the initiation of buprenorphine within one year of the earliest OUD clinical encounter (i.e., index date) using VHA Pharmacy Benefits Management records for any formulations of buprenorphine or buprenorphine/naloxone indicated for OUD [<xref ref-type="bibr" rid="CR14">14</xref>]. Prescriptions for the buprenorphine transdermal patch, indicated for pain management, were excluded [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR38">38</xref>]. As in previous studies, six- and 12-month buprenorphine retention were defined as <italic toggle="yes">&#8805;</italic>&#8201;80% proportion of days covered in the six months and year following buprenorphine initiation, respectively [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR40">40</xref>].</p><p id="Par10">Patient demographic and health characteristics, including age, sex, race/ethnicity (categorized as non-Hispanic White, non-Hispanic Black, Hispanic, and other), HIV status, smoking status (categorized as never, current, and past), and pain intensity rating closest to the first (index) OUD encounter date were obtained from the VHA Corporate Data Warehouse. Smoking status is assessed and documented annually on all VHA patients [<xref ref-type="bibr" rid="CR41">41</xref>]; it was included given reported disparities in smoking status among VACS patients with SUDs with and without HIV [<xref ref-type="bibr" rid="CR8">8</xref>], and the association between smoking status and OUD behavioral treatment intensity among VACS patients [<xref ref-type="bibr" rid="CR42">42</xref>]. Self-reported pain intensity ratings, measured on a scale of 0 (no pain) to 10 (worst pain imaginable), were dichotomized as no pain/mild pain (less than 4) and moderate/severe pain (4 or greater) [<xref ref-type="bibr" rid="CR43">43</xref>&#8211;<xref ref-type="bibr" rid="CR45">45</xref>]. Among PWH, receipt of antiretroviral medications during the year before and after the index OUD encounter date were utilized. Four pain (fibromyalgia; headache; limb/extremity, joint, or arthritic pain; and neuropathic pain) [<xref ref-type="bibr" rid="CR46">46</xref>], six non-opioid substance use (alcohol, cocaine, cannabis, amphetamines, sedatives, and hallucinogens), and six mental health (major depressive disorder, other depression, post-traumatic stress disorder, anxiety disorder, bipolar disorder, and schizophrenia) co-occurring diagnoses were selected based on past literature [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR38">38</xref>]. To identify patients with common pain conditions specifically, diagnoses were ascertained from ICD-9 and ICD-10 codes using the crosswalk developed by Mayhew et al. [<xref ref-type="bibr" rid="CR46">46</xref>].</p></sec><sec id="Sec5"><title>Statistical Analysis</title><p id="Par11">To identify patterns of co-occurring pain conditions, SUDs, and mental health diagnoses in OUD patients with and without HIV, a LCA was utilized. LCA, which has previously been used to better understand SUDs, is a statistical method for identifying meaningful segments, or classes, within a population [<xref ref-type="bibr" rid="CR24">24</xref>&#8211;<xref ref-type="bibr" rid="CR27">27</xref>]. The LCA included sixteen indicators: four types of pain diagnoses; six SUDs, and six mental health diagnoses, as described above. The optimal number of classes was selected based on Bayesian Information Criteria (BIC), with consideration given to average posterior probability (i.e., the likelihood of class membership for each observation; a 70% threshold is well established as acceptable) [<xref ref-type="bibr" rid="CR47">47</xref>], interpretability and class size (we required the smallest class to have at least 5% prevalence) [<xref ref-type="bibr" rid="CR27">27</xref>]. The LCA was performed for two to six class solutions, after which increasing numbers of classes provided no benefit to fit statistics. Patients were assigned to a class for which they had the highest estimated probability of membership. Differences in class membership based on patient characteristics, including demographic and health characteristics, were analyzed using chi-square and ANOVA for categorical and continuous variables, respectively.</p><p id="Par12">Bivariate and multivariable logistic regression analyses were then used to analyze the association of class membership with three outcomes: buprenorphine initiation within 12 months of the index OUD encounter and six- and 12-month retention among those who initiated buprenorphine. In adjusted multivariable models, age, sex, race/ethnicity, smoking status, and HIV status were included as covariates, with an HIV status-class membership interaction term. Multicollinearity was assessed using variance inflation factor testing. None of the variables included in the LCA had missing data. One covariate in the regression model had low levels of missing data (smoking status, missing&#8201;=&#8201;0.3%); complete case analysis was used in the regression analyses. Stata (15.1; College Station, TX) was used for the analysis, with two-sided test of <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.05 denoting statistical significance.</p></sec></sec><sec id="Sec6" sec-type="results"><title>Results</title><sec id="Sec7"><title>Sample Characteristics</title><p id="Par13">During the baseline period of January 2008 to September 2017, a total of 7,875 patients had an index OUD clinical encounter, including 2,702 (34.3%) PWH and 5,173 PWoH (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). The sample predominately consisted of non-Hispanic Black (58.2%), males (97.8%), and those who reported current smoking (79.6%). The most common past-year, co-occurring SUD diagnoses were alcohol (47.4%), cocaine (32.7%), and cannabis (15.5%). Several co-occurring pain and mental health conditions were more common among PWoH than PWH, including limb, joint, or arthritic pain (51.9% vs. 38.7%, &#935;<sup>2</sup>&#8201;=&#8201;123.88, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001); neuropathic pain (22.1% vs. 15.9%, &#935;<sup>2</sup>&#8201;=&#8201;42.43, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001); post-traumatic stress disorder (28.9% vs. 21.2%, &#935;<sup>2</sup>&#8201;=&#8201;55.05, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001); and schizophrenia (10.9% vs. 8.5%, &#935;<sup>2</sup>&#8201;=&#8201;10.50, <italic toggle="yes">p</italic>&#8201;=&#8201;0.001). The majority of PWH in the sample were receiving antiretrovirals before their OUD index visit (70.4%) and this proportion increased following OUD diagnosis (78.0%, &#935;<sup>2</sup>&#8201;=&#8201;1,400, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001).</p><p id="Par31">
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Demographic and health characteristics of patients with at least one index OUD episode by HIV status</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Baseline Characteristics</th><th align="left" colspan="1" rowspan="1">Total Sample <break/>(<italic toggle="yes">n</italic>&#8201;=&#8201;7,875)</th><th align="left" colspan="1" rowspan="1">PWH<break/>(<italic toggle="yes">n</italic>&#8201;=&#8201;2,702)</th><th align="left" colspan="1" rowspan="1">PWoH<break/>(<italic toggle="yes">n</italic>&#8201;=&#8201;5,173)</th><th align="left" colspan="1" rowspan="1">Test Statistic</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Age, mean years (SD)</td><td align="left" colspan="1" rowspan="1">54.7 (7.77)</td><td char="." align="char" colspan="1" rowspan="1">54.9 (7.57)</td><td align="left" colspan="1" rowspan="1">54.6 (7.88)</td><td align="left" colspan="1" rowspan="1">1.66</td><td align="left" colspan="1" rowspan="1">0.198</td></tr><tr><td align="left" colspan="1" rowspan="1">Male Sex, n (%)</td><td align="left" colspan="1" rowspan="1">7,704 (97.8)</td><td char="." align="char" colspan="1" rowspan="1">2,623 (97.1)</td><td align="left" colspan="1" rowspan="1">5,081 (98.2)</td><td align="left" colspan="1" rowspan="1">10.96</td><td align="left" colspan="1" rowspan="1">0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Race/ethnicity, n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">38.47</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;White</td><td align="left" colspan="1" rowspan="1">2,536 (32.3)</td><td char="." align="char" colspan="1" rowspan="1">768 (28.4)</td><td align="left" colspan="1" rowspan="1">1,768 (34.2)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Black</td><td align="left" colspan="1" rowspan="1">4,583 (58.2)</td><td char="." align="char" colspan="1" rowspan="1">1,626 (60.2)</td><td align="left" colspan="1" rowspan="1">2,957 (57.2)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Hispanic</td><td align="left" colspan="1" rowspan="1">657 (8.3)</td><td char="." align="char" colspan="1" rowspan="1">276 (10.2)</td><td align="left" colspan="1" rowspan="1">381 (7.4)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Other/unknown</td><td align="left" colspan="1" rowspan="1">99 (1.3)</td><td char="." align="char" colspan="1" rowspan="1">32 (1.2)</td><td align="left" colspan="1" rowspan="1">67 (1.3)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Smoking Status, n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">7.25</td><td align="left" colspan="1" rowspan="1">0.027</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Never</td><td align="left" colspan="1" rowspan="1">840 (10.7)</td><td char="." align="char" colspan="1" rowspan="1">254 (9.4)</td><td align="left" colspan="1" rowspan="1">586 (11.3)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Current</td><td align="left" colspan="1" rowspan="1">6,267 (79.6)</td><td char="." align="char" colspan="1" rowspan="1">2,188 (81.0)</td><td align="left" colspan="1" rowspan="1">4,079 (78.8)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Past</td><td align="left" colspan="1" rowspan="1">747 (9.5)</td><td char="." align="char" colspan="1" rowspan="1">253 (9.4)</td><td align="left" colspan="1" rowspan="1">494 (9.5)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Missing</td><td align="left" colspan="1" rowspan="1">21 (0.3)</td><td char="." align="char" colspan="1" rowspan="1">7 (0.3)</td><td align="left" colspan="1" rowspan="1">14 (0.3)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Pain Intensity, mean (SD)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Highest Pain Level</td><td align="left" colspan="1" rowspan="1">6.8 (3.31)</td><td char="." align="char" colspan="1" rowspan="1">6.7 (3.40)</td><td align="left" colspan="1" rowspan="1">6.9 (3.25)</td><td align="left" colspan="1" rowspan="1">3.91</td><td align="left" colspan="1" rowspan="1">0.048</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Closest Pain Level</td><td align="left" colspan="1" rowspan="1">3.7 (3.68)</td><td char="." align="char" colspan="1" rowspan="1">3.2 (3.66)</td><td align="left" colspan="1" rowspan="1">4.0 (3.66)</td><td align="left" colspan="1" rowspan="1">71.14</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Missing</td><td align="left" colspan="1" rowspan="1">262 (3.3)</td><td char="." align="char" colspan="1" rowspan="1">99 (3.7)</td><td align="left" colspan="1" rowspan="1">163 (3.2)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Pain Diagnoses, n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Fibromyalgia</td><td align="left" colspan="1" rowspan="1">241 (3.1)</td><td char="." align="char" colspan="1" rowspan="1">70 (2.6)</td><td align="left" colspan="1" rowspan="1">171 (3.3)</td><td align="left" colspan="1" rowspan="1">3.06</td><td align="left" colspan="1" rowspan="1">0.080</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Headache</td><td align="left" colspan="1" rowspan="1">733 (9.3)</td><td char="." align="char" colspan="1" rowspan="1">229 (8.5)</td><td align="left" colspan="1" rowspan="1">504 (9.7)</td><td align="left" colspan="1" rowspan="1">3.38</td><td align="left" colspan="1" rowspan="1">0.066</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Limb/extremity, Joint, or Arthritic Pain</td><td align="left" colspan="1" rowspan="1">3,728 (47.3)</td><td char="." align="char" colspan="1" rowspan="1">1,045 (38.7)</td><td align="left" colspan="1" rowspan="1">2,683 (51.9)</td><td align="left" colspan="1" rowspan="1">123.88</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Neuropathic Pain</td><td align="left" colspan="1" rowspan="1">1,573 (20.0)</td><td char="." align="char" colspan="1" rowspan="1">430 (15.9)</td><td align="left" colspan="1" rowspan="1">1,143 (22.1)</td><td align="left" colspan="1" rowspan="1">42.43</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Mental Health Conditions, n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Major Depressive Disorder</td><td align="left" colspan="1" rowspan="1">2,014 (25.6)</td><td char="." align="char" colspan="1" rowspan="1">682 (25.2)</td><td align="left" colspan="1" rowspan="1">1,332 (25.7)</td><td align="left" colspan="1" rowspan="1">0.24</td><td align="left" colspan="1" rowspan="1">0.623</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Other Depression</td><td align="left" colspan="1" rowspan="1">3,787 (48.1)</td><td char="." align="char" colspan="1" rowspan="1">1,316 (48.7)</td><td align="left" colspan="1" rowspan="1">2,471 (47.8)</td><td align="left" colspan="1" rowspan="1">0.62</td><td align="left" colspan="1" rowspan="1">0.429</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Post-Traumatic Stress Disorder</td><td align="left" colspan="1" rowspan="1">2,068 (26.3)</td><td char="." align="char" colspan="1" rowspan="1">572 (21.2)</td><td align="left" colspan="1" rowspan="1">1,496 (28.9)</td><td align="left" colspan="1" rowspan="1">55.05</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Anxiety Disorder</td><td align="left" colspan="1" rowspan="1">1,421 (18.0)</td><td char="." align="char" colspan="1" rowspan="1">462 (17.1)</td><td align="left" colspan="1" rowspan="1">959 (18.5)</td><td align="left" colspan="1" rowspan="1">2.49</td><td align="left" colspan="1" rowspan="1">0.115</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Bipolar Disorder</td><td align="left" colspan="1" rowspan="1">1,012 (12.9)</td><td char="." align="char" colspan="1" rowspan="1">336 (12.4)</td><td align="left" colspan="1" rowspan="1">676 (13.1)</td><td align="left" colspan="1" rowspan="1">0.63</td><td align="left" colspan="1" rowspan="1">0.426</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Schizophrenia</td><td align="left" colspan="1" rowspan="1">793 (10.1)</td><td char="." align="char" colspan="1" rowspan="1">231 (8.5)</td><td align="left" colspan="1" rowspan="1">562 (10.9)</td><td align="left" colspan="1" rowspan="1">10.50</td><td align="left" colspan="1" rowspan="1">0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Substance Use Disorders, n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Substance Use Disorder (Including Opioid)</td><td align="left" colspan="1" rowspan="1">7,824 (99.4)</td><td char="." align="char" colspan="1" rowspan="1">2,672 (98.9)</td><td align="left" colspan="1" rowspan="1">5,152 (99.6)</td><td align="left" colspan="1" rowspan="1">13.68</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Non-Opioid Substance Use Disorder</td><td align="left" colspan="1" rowspan="1">4,565 (58.0)</td><td char="." align="char" colspan="1" rowspan="1">1,611 (59.6)</td><td align="left" colspan="1" rowspan="1">2,954 (57.1)</td><td align="left" colspan="1" rowspan="1">4.62</td><td align="left" colspan="1" rowspan="1">0.032</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Alcohol Use Disorder</td><td align="left" colspan="1" rowspan="1">3,734 (47.4)</td><td char="." align="char" colspan="1" rowspan="1">1,249 (46.2)</td><td align="left" colspan="1" rowspan="1">2,485 (48.0)</td><td align="left" colspan="1" rowspan="1">2.34</td><td align="left" colspan="1" rowspan="1">0.126</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Cocaine</td><td align="left" colspan="1" rowspan="1">2,578 (32.7)</td><td char="." align="char" colspan="1" rowspan="1">1,007 (37.3)</td><td align="left" colspan="1" rowspan="1">1,571 (30.4)</td><td align="left" colspan="1" rowspan="1">38.37</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Cannabis</td><td align="left" colspan="1" rowspan="1">1,217 (15.5)</td><td char="." align="char" colspan="1" rowspan="1">409 (15.1)</td><td align="left" colspan="1" rowspan="1">808 (15.6)</td><td align="left" colspan="1" rowspan="1">0.32</td><td align="left" colspan="1" rowspan="1">0.574</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Amphetamines</td><td align="left" colspan="1" rowspan="1">291 (3.7)</td><td char="." align="char" colspan="1" rowspan="1">145 (5.4)</td><td align="left" colspan="1" rowspan="1">146 (2.8)</td><td align="left" colspan="1" rowspan="1">32.28</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Sedatives</td><td align="left" colspan="1" rowspan="1">184 (2.3)</td><td char="." align="char" colspan="1" rowspan="1">59 (2.2)</td><td align="left" colspan="1" rowspan="1">125 (2.4)</td><td align="left" colspan="1" rowspan="1">0.42</td><td align="left" colspan="1" rowspan="1">0.516</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Hallucinogens</td><td align="left" colspan="1" rowspan="1">33 (0.4)</td><td char="." align="char" colspan="1" rowspan="1">12 (0.4)</td><td align="left" colspan="1" rowspan="1">21 (0.4)</td><td align="left" colspan="1" rowspan="1">0.06</td><td align="left" colspan="1" rowspan="1">0.803</td></tr><tr><td align="left" colspan="4" rowspan="1">Receiving Antiretroviral Therapy, n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Before OUD Diagnosis</td><td align="left" colspan="1" rowspan="1">---</td><td char="." align="char" colspan="1" rowspan="1">1,901 (70.4)</td><td align="left" colspan="1" rowspan="1">---</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;After OUD Diagnosis</td><td align="left" colspan="1" rowspan="1">---</td><td char="." align="char" colspan="1" rowspan="1">2,108 (78.0)</td><td align="left" colspan="1" rowspan="1">---</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr></tbody></table></table-wrap>
</p></sec><sec id="Sec8"><title>Latent Class Solution</title><p id="Par14">The latent class solution with four classes was selected given the lower BIC (6407) than the two (7693) and three (6646) class solutions (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). While the four-class BIC was higher than those of the five (6305) and six (6332) class solutions and the both five- and six-class solutions also met class size criteria of at least 5% prevalence in each class (14.2% and 5.0%, respectively), both the five and six class solutions had one class with very low average posterior probability (60.0% and 59.0%, respectively). The average of the maximum posterior probabilities for the four class solution ranged from 72.0 to 81.0%, with an overall average of 76.0%.</p><p id="Par32">
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Fit indices for two through six class models of co-occurring pain, mental health, and substance use diagnoses among patients with OUD</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1"># of classes</th><th align="left" colspan="1" rowspan="1">Log-Likelihood</th><th align="left" colspan="1" rowspan="1">AIC</th><th align="left" colspan="1" rowspan="1">BIC</th><th align="left" colspan="1" rowspan="1">CAIC</th><th align="left" colspan="1" rowspan="1">Adjusted BIC</th><th align="left" colspan="1" rowspan="1">Entropy</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">2</td><td align="left" colspan="1" rowspan="1">-50732.77</td><td align="left" colspan="1" rowspan="1">7462.62</td><td align="left" colspan="1" rowspan="1">7692.68</td><td align="left" colspan="1" rowspan="1">7725.68</td><td align="left" colspan="1" rowspan="1">7587.81</td><td align="left" colspan="1" rowspan="1">0.65</td></tr><tr><td align="left" colspan="1" rowspan="1">3</td><td align="left" colspan="1" rowspan="1">-50133.20</td><td align="left" colspan="1" rowspan="1">6297.49</td><td align="left" colspan="1" rowspan="1">6646.06</td><td align="left" colspan="1" rowspan="1">6696.06</td><td align="left" colspan="1" rowspan="1">6487.17</td><td align="left" colspan="1" rowspan="1">0.60</td></tr><tr><td align="left" colspan="1" rowspan="1">
<bold>4</bold>
</td><td align="left" colspan="1" rowspan="1">
<bold>-49937.52</bold>
</td><td align="left" colspan="1" rowspan="1">
<bold>5940.12</bold>
</td><td align="left" colspan="1" rowspan="1">
<bold>6407.21</bold>
</td><td align="left" colspan="1" rowspan="1">
<bold>6474.21</bold>
</td><td align="left" colspan="1" rowspan="1">
<bold>6194.29</bold>
</td><td align="left" colspan="1" rowspan="1">
<bold>0.59</bold>
</td></tr><tr><td align="left" colspan="1" rowspan="1">5</td><td align="left" colspan="1" rowspan="1">-49810.22</td><td align="left" colspan="1" rowspan="1">5719.52</td><td align="left" colspan="1" rowspan="1">6305.12</td><td align="left" colspan="1" rowspan="1">6389.12</td><td align="left" colspan="1" rowspan="1">6038.18</td><td align="left" colspan="1" rowspan="1">0.56</td></tr><tr><td align="left" colspan="1" rowspan="1">6</td><td align="left" colspan="1" rowspan="1">-49747.24</td><td align="left" colspan="1" rowspan="1">5627.56</td><td align="left" colspan="1" rowspan="1">6331.67</td><td align="left" colspan="1" rowspan="1">6432.67</td><td align="left" colspan="1" rowspan="1">6010.72</td><td align="left" colspan="1" rowspan="1">0.54</td></tr></tbody></table><table-wrap-foot><p>AIC, Akaike information criterion; BIC, Bayesian information criterion; CAIC, Consistent Akaike information criterion</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec9"><title>Patterns of Co-occurring Diagnoses across Latent Classes</title><p id="Par15">Based on the prevalence of co-occurring diagnoses in each class, the four identified classes were coined the &#8220;Few Co-occurring Diagnoses&#8221; (<italic toggle="yes">n</italic>&#8201;=&#8201;3,328; 42.3%); &#8220;Multiple Pain Conditions&#8221; (<italic toggle="yes">n</italic>&#8201;=&#8201;1,681; 21.3%); &#8220;Pain&#8201;+&#8201;SUD&#8221; (<italic toggle="yes">n</italic>&#8201;=&#8201;1,449; 18.4%); and &#8220;Pain&#8201;+&#8201;SUD&#8201;+&#8201;Mental Health&#8221; (<italic toggle="yes">n</italic>&#8201;=&#8201;1,417, 18.0%) (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>).</p><p id="Par33">
<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Demographic and clinical differences between four classes of patients with OUD</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Baseline Characteristics</th><th align="left" colspan="1" rowspan="1">Class 1: Few Co-occurring Diagnoses<break/>(<italic toggle="yes">n</italic>&#8201;=&#8201;3,328)</th><th align="left" colspan="1" rowspan="1">Class 2: Multiple Pain Conditions<break/>(<italic toggle="yes">n</italic>&#8201;=&#8201;1,681)</th><th align="left" colspan="1" rowspan="1">Class 3: Co-occurring Pain&#8201;+&#8201;SUD<break/>(<italic toggle="yes">n</italic>&#8201;=&#8201;1,449)</th><th align="left" colspan="1" rowspan="1">Class 4: Co-occurring Pain, SUD, and Mental Health<break/>(<italic toggle="yes">n</italic>&#8201;=&#8201;1,417)</th><th align="left" colspan="1" rowspan="1">Test Statistic</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">p</italic>-value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Proportion of Total Sample</td><td align="left" colspan="1" rowspan="1">42.3%</td><td align="left" colspan="1" rowspan="1">21.3%</td><td align="left" colspan="1" rowspan="1">18.4%</td><td align="left" colspan="1" rowspan="1">18.0%</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Age, mean years (SD)</td><td align="left" colspan="1" rowspan="1">55.2 (7.76)</td><td align="left" colspan="1" rowspan="1">55.1 (8.50)</td><td align="left" colspan="1" rowspan="1">54.8 (6.32)</td><td align="left" colspan="1" rowspan="1">52.9 (7.99)</td><td align="left" colspan="1" rowspan="1">31.26</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Male Sex, n (%)</td><td align="left" colspan="1" rowspan="1">3,278 (98.5)</td><td align="left" colspan="1" rowspan="1">1,623 (96.5)</td><td align="left" colspan="1" rowspan="1">1,428 (98.6)</td><td align="left" colspan="1" rowspan="1">1,375 (97.0)</td><td align="left" colspan="1" rowspan="1">27.70</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Race/ethnicity, n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">458.03</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;White</td><td align="left" colspan="1" rowspan="1">1,014 (30.5)</td><td align="left" colspan="1" rowspan="1">794 (47.2)</td><td align="left" colspan="1" rowspan="1">222 (15.3)</td><td align="left" colspan="1" rowspan="1">506 (35.7)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Black</td><td align="left" colspan="1" rowspan="1">1,914 (57.5)</td><td align="left" colspan="1" rowspan="1">744 (44.3)</td><td align="left" colspan="1" rowspan="1">1,132 (78.1)</td><td align="left" colspan="1" rowspan="1">793 (56.0)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Hispanic</td><td align="left" colspan="1" rowspan="1">350 (10.5)</td><td align="left" colspan="1" rowspan="1">118 (7.0)</td><td align="left" colspan="1" rowspan="1">91 (6.3)</td><td align="left" colspan="1" rowspan="1">98 (6.9)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Other/unknown</td><td align="left" colspan="1" rowspan="1">50 (1.5)</td><td align="left" colspan="1" rowspan="1">25 (1.5)</td><td align="left" colspan="1" rowspan="1">4 (0.3)</td><td align="left" colspan="1" rowspan="1">20 (1.4)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Smoking Status, n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">152.67</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Never</td><td align="left" colspan="1" rowspan="1">309 (9.3)</td><td align="left" colspan="1" rowspan="1">263 (15.6)</td><td align="left" colspan="1" rowspan="1">117 (8.1)</td><td align="left" colspan="1" rowspan="1">151 (10.7)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Current</td><td align="left" colspan="1" rowspan="1">2,683 (80.6)</td><td align="left" colspan="1" rowspan="1">1,174 (69.8)</td><td align="left" colspan="1" rowspan="1">1,250 (86.3)</td><td align="left" colspan="1" rowspan="1">1,160 (81.9)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Past</td><td align="left" colspan="1" rowspan="1">322 (9.7)</td><td align="left" colspan="1" rowspan="1">239 (14.2)</td><td align="left" colspan="1" rowspan="1">82 (5.7)</td><td align="left" colspan="1" rowspan="1">104 (7.3)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Missing</td><td align="left" colspan="1" rowspan="1">14 (0.4)</td><td align="left" colspan="1" rowspan="1">5 (0.3)</td><td align="left" colspan="1" rowspan="1">0 (0.0)</td><td align="left" colspan="1" rowspan="1">2 (0.1)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Closest Pain Intensity Rating: Moderate to Severe, n (%)</td><td align="left" colspan="1" rowspan="1">1,376 (41.3)</td><td align="left" colspan="1" rowspan="1">1,124 (66.9)</td><td align="left" colspan="1" rowspan="1">587 (40.5)</td><td align="left" colspan="1" rowspan="1">672 (47.4)</td><td align="left" colspan="1" rowspan="1">289.30</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Missing</td><td align="left" colspan="1" rowspan="1">216 (6.5)</td><td align="left" colspan="1" rowspan="1">13 (0.7)</td><td align="left" colspan="1" rowspan="1">24 (1.7)</td><td align="left" colspan="1" rowspan="1">9 (0.6)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Pain Diagnoses, n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Fibromyalgia</td><td align="left" colspan="1" rowspan="1">6 (0.2)</td><td align="left" colspan="1" rowspan="1">168 (10.0)</td><td align="left" colspan="1" rowspan="1">36 (2.5)</td><td align="left" colspan="1" rowspan="1">31 (2.2)</td><td align="left" colspan="1" rowspan="1">370.72</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Headache</td><td align="left" colspan="1" rowspan="1">98 (2.9)</td><td align="left" colspan="1" rowspan="1">332 (19.8)</td><td align="left" colspan="1" rowspan="1">88 (6.1)</td><td align="left" colspan="1" rowspan="1">215 (15.2)</td><td align="left" colspan="1" rowspan="1">452.47</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Limb/extremity, Joint,&#160;or Arthritic Pain</td><td align="left" colspan="1" rowspan="1">863 (25.9)</td><td align="left" colspan="1" rowspan="1">1,320 (78.5)</td><td align="left" colspan="1" rowspan="1">659 (45.5)</td><td align="left" colspan="1" rowspan="1">886 (62.5)</td><td align="left" colspan="1" rowspan="1">1,400</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Neuropathic Pain</td><td align="left" colspan="1" rowspan="1">65 (2.0)</td><td align="left" colspan="1" rowspan="1">1,003 (59.7)</td><td align="left" colspan="1" rowspan="1">146 (10.1)</td><td align="left" colspan="1" rowspan="1">359 (25.3)</td><td align="left" colspan="1" rowspan="1">2,400</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Mental Health Conditions, n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Major Depressive Disorder</td><td align="left" colspan="1" rowspan="1">312 (9.4)</td><td align="left" colspan="1" rowspan="1">560 (33.3)</td><td align="left" colspan="1" rowspan="1">219 (15.1)</td><td align="left" colspan="1" rowspan="1">923 (65.1)</td><td align="left" colspan="1" rowspan="1">1,800</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Other Depression</td><td align="left" colspan="1" rowspan="1">914 (27.5)</td><td align="left" colspan="1" rowspan="1">937 (55.7)</td><td align="left" colspan="1" rowspan="1">701 (48.4)</td><td align="left" colspan="1" rowspan="1">1,235 (87.2)</td><td align="left" colspan="1" rowspan="1">1,500</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Post-Traumatic Stress Disorder</td><td align="left" colspan="1" rowspan="1">412 (12.4)</td><td align="left" colspan="1" rowspan="1">624 (37.1)</td><td align="left" colspan="1" rowspan="1">355 (24.5)</td><td align="left" colspan="1" rowspan="1">677 (47.8)</td><td align="left" colspan="1" rowspan="1">774.62</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Anxiety Disorder</td><td align="left" colspan="1" rowspan="1">216 (6.5)</td><td align="left" colspan="1" rowspan="1">539 (32.1)</td><td align="left" colspan="1" rowspan="1">18 (1.2)</td><td align="left" colspan="1" rowspan="1">648 (45.7)</td><td align="left" colspan="1" rowspan="1">1,500</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Bipolar Disorder</td><td align="left" colspan="1" rowspan="1">181 (5.4)</td><td align="left" colspan="1" rowspan="1">171 (10.2)</td><td align="left" colspan="1" rowspan="1">205 (14.1)</td><td align="left" colspan="1" rowspan="1">455 (32.1)</td><td align="left" colspan="1" rowspan="1">645.51</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Schizophrenia</td><td align="left" colspan="1" rowspan="1">214 (6.4)</td><td align="left" colspan="1" rowspan="1">64 (3.8)</td><td align="left" colspan="1" rowspan="1">295 (20.4)</td><td align="left" colspan="1" rowspan="1">220 (15.5)</td><td align="left" colspan="1" rowspan="1">337.45</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Substance Use Disorders, n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Alcohol Use Disorder</td><td align="left" colspan="1" rowspan="1">954 (28.7)</td><td align="left" colspan="1" rowspan="1">328 (19.5)</td><td align="left" colspan="1" rowspan="1">1,207 (83.3)</td><td align="left" colspan="1" rowspan="1">1,245 (87.9)</td><td align="left" colspan="1" rowspan="1">2,700</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Cocaine</td><td align="left" colspan="1" rowspan="1">179 (5.4)</td><td align="left" colspan="1" rowspan="1">73 (4.3)</td><td align="left" colspan="1" rowspan="1">1,394 (96.2)</td><td align="left" colspan="1" rowspan="1">932 (65.8)</td><td align="left" colspan="1" rowspan="1">5,100</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Cannabis</td><td align="left" colspan="1" rowspan="1">37 (1.1)</td><td align="left" colspan="1" rowspan="1">72 (4.3)</td><td align="left" colspan="1" rowspan="1">530 (36.6)</td><td align="left" colspan="1" rowspan="1">578 (40.8)</td><td align="left" colspan="1" rowspan="1">1,900</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Amphetamines</td><td align="left" colspan="1" rowspan="1">37 (1.1)</td><td align="left" colspan="1" rowspan="1">7 (0.4)</td><td align="left" colspan="1" rowspan="1">17 (1.2)</td><td align="left" colspan="1" rowspan="1">230 (16.2)</td><td align="left" colspan="1" rowspan="1">764.87</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Sedatives</td><td align="left" colspan="1" rowspan="1">6 (0.2)</td><td align="left" colspan="1" rowspan="1">38 (2.3)</td><td align="left" colspan="1" rowspan="1">12 (0.8)</td><td align="left" colspan="1" rowspan="1">128 (9.0)</td><td align="left" colspan="1" rowspan="1">360.77</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Hallucinogens</td><td align="left" colspan="1" rowspan="1">3 (0.1)</td><td align="left" colspan="1" rowspan="1">0 (0.0)</td><td align="left" colspan="1" rowspan="1">10 (0.7)</td><td align="left" colspan="1" rowspan="1">20 (1.4)</td><td align="left" colspan="1" rowspan="1">51.69</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;HIV Seropositive, n (%)</td><td align="left" colspan="1" rowspan="1">1,234 (37.1)</td><td align="left" colspan="1" rowspan="1">419 (24.9)</td><td align="left" colspan="1" rowspan="1">566 (39.1)</td><td align="left" colspan="1" rowspan="1">483 (34.1)</td><td align="left" colspan="1" rowspan="1">91.55</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">Receiving Antiretroviral Therapy, n (%)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Before OUD Diagnosis</td><td align="left" colspan="1" rowspan="1">773 (62.6)</td><td align="left" colspan="1" rowspan="1">323 (77.1)</td><td align="left" colspan="1" rowspan="1">434 (76.7)</td><td align="left" colspan="1" rowspan="1">371 (76.8)</td><td align="left" colspan="1" rowspan="1">64.81</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;After OUD Diagnosis</td><td align="left" colspan="1" rowspan="1">925 (75.0)</td><td align="left" colspan="1" rowspan="1">335 (80.0)</td><td align="left" colspan="1" rowspan="1">462 (81.6)</td><td align="left" colspan="1" rowspan="1">386 (79.9)</td><td align="left" colspan="1" rowspan="1">12.96</td><td align="left" colspan="1" rowspan="1">0.005</td></tr></tbody></table></table-wrap>
</p><p id="Par34">
<table-wrap id="Tab4" position="float" orientation="portrait"><label>Table 4</label><caption><p>Predictors of buprenorphine initiation and retention (six-month and 12-month) in a multivariable regression analysis</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">Predictors</th><th align="left" colspan="3" rowspan="1">Initiated Buprenorphine<break/>(<italic toggle="yes">n</italic>&#8201;=&#8201;7,875)<sup>a</sup></th><th align="left" colspan="3" rowspan="1">Retained at 6 Months<break/>(<italic toggle="yes">n</italic>&#8201;=&#8201;635)<sup>a</sup></th><th align="left" colspan="3" rowspan="1">Retained at 12 Months<break/>(<italic toggle="yes">n</italic>&#8201;=&#8201;635)<sup>a</sup></th></tr><tr><th align="left" colspan="1" rowspan="1">n (%)</th><th align="left" colspan="1" rowspan="1">aOR (95% CI)</th><th align="left" colspan="1" rowspan="1">p-value</th><th align="left" colspan="1" rowspan="1">n (%)</th><th align="left" colspan="1" rowspan="1">aOR (95% CI)</th><th align="left" colspan="1" rowspan="1">p-value</th><th align="left" colspan="1" rowspan="1">n (%)</th><th align="left" colspan="1" rowspan="1">aOR (95% CI)</th><th align="left" colspan="1" rowspan="1">p-value</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Class Membership</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Class 1: Few Co-occurring Diagnoses</td><td align="left" colspan="1" rowspan="1">330 (9.9)</td><td align="left" colspan="1" rowspan="1">ref</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">141 (42.7)</td><td align="left" colspan="1" rowspan="1">ref</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">99 (30.0)</td><td align="left" colspan="1" rowspan="1">ref</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Class 2: Multiple Pain Conditions</td><td align="left" colspan="1" rowspan="1">158 (9.4)</td><td align="left" colspan="1" rowspan="1">0.87 (0.68, 1.12)</td><td align="left" colspan="1" rowspan="1">0.261</td><td align="left" colspan="1" rowspan="1">72 (45.6)</td><td align="left" colspan="1" rowspan="1">1.20 (0.75, 1.93)</td><td align="left" colspan="1" rowspan="1">0.447</td><td align="left" colspan="1" rowspan="1">44 (27.8)</td><td align="left" colspan="1" rowspan="1">0.98 (0.59, 1.62)</td><td align="left" colspan="1" rowspan="1">0.935</td></tr><tr><td align="left" colspan="1" rowspan="1">Class 3: Pain&#8201;+&#8201;SUD</td><td align="left" colspan="1" rowspan="1">55 (3.8)</td><td align="left" colspan="1" rowspan="1">0.41 (0.28, 0.59)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">21 (38.2)</td><td align="left" colspan="1" rowspan="1">0.92 (0.44, 1.92)</td><td align="left" colspan="1" rowspan="1">0.830</td><td align="left" colspan="1" rowspan="1">15 (27.3)</td><td align="left" colspan="1" rowspan="1">0.86 (0.38, 1.96)</td><td align="left" colspan="1" rowspan="1">0.722</td></tr><tr><td align="left" colspan="1" rowspan="1">Class 4: Pain&#8201;+&#8201;SUD&#8201;+&#8201;Mental Health</td><td align="left" colspan="1" rowspan="1">92 (6.5)</td><td align="left" colspan="1" rowspan="1">0.55 (0.41, 0.75)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">41 (44.6)</td><td align="left" colspan="1" rowspan="1">1.20 (0.67, 2.18)</td><td align="left" colspan="1" rowspan="1">0.539</td><td align="left" colspan="1" rowspan="1">26 (28.3)</td><td align="left" colspan="1" rowspan="1">0.92 (0.48, 1.76)</td><td align="left" colspan="1" rowspan="1">0.803</td></tr><tr><td align="left" colspan="1" rowspan="1">Age</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.97 (0.96, 0.98)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1.00 (0.98, 1.02)</td><td align="left" colspan="1" rowspan="1">0.779</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.99 (0.98, 1.02)</td><td align="left" colspan="1" rowspan="1">0.870</td></tr><tr><td align="left" colspan="1" rowspan="1">Sex</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Female</td><td align="left" colspan="1" rowspan="1">13 (7.6)</td><td align="left" colspan="1" rowspan="1">ref</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">5 (38.5)</td><td align="left" colspan="1" rowspan="1">ref</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1 (7.7)</td><td align="left" colspan="1" rowspan="1">ref</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Male</td><td align="left" colspan="1" rowspan="1">622 (8.1)</td><td align="left" colspan="1" rowspan="1">1.21 (0.68, 2.16)</td><td align="left" colspan="1" rowspan="1">0.520</td><td align="left" colspan="1" rowspan="1">270 (43.4)</td><td align="left" colspan="1" rowspan="1">1.13 (0.35, 3.62)</td><td align="left" colspan="1" rowspan="1">0.833</td><td align="left" colspan="1" rowspan="1">183 (29.4)</td><td align="left" colspan="1" rowspan="1">4.74 (0.60, 37.42)</td><td align="left" colspan="1" rowspan="1">0.140</td></tr><tr><td align="left" colspan="1" rowspan="1">Race/ethnicity</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;White</td><td align="left" colspan="1" rowspan="1">266 (10.5)</td><td align="left" colspan="1" rowspan="1">ref</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">141 (53.0)</td><td align="left" colspan="1" rowspan="1">ref</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">94 (35.3)</td><td align="left" colspan="1" rowspan="1">ref</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Black</td><td align="left" colspan="1" rowspan="1">307 (6.7)</td><td align="left" colspan="1" rowspan="1">0.72 (0.60, 0.86)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">109 (35.5)</td><td align="left" colspan="1" rowspan="1">0.48 (0.34, 0.69)</td><td align="left" colspan="1" rowspan="1">&lt;&#8201;0.001</td><td align="left" colspan="1" rowspan="1">71 (23.1)</td><td align="left" colspan="1" rowspan="1">0.53 (0.37, 0.78)</td><td align="left" colspan="1" rowspan="1">0.001</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Hispanic</td><td align="left" colspan="1" rowspan="1">51 (7.8)</td><td align="left" colspan="1" rowspan="1">0.77 (0.56, 1.06)</td><td align="left" colspan="1" rowspan="1">0.114</td><td align="left" colspan="1" rowspan="1">20 (39.2)</td><td align="left" colspan="1" rowspan="1">0.57 (0.30, 1.06)</td><td align="left" colspan="1" rowspan="1">0.074</td><td align="left" colspan="1" rowspan="1">16 (31.4)</td><td align="left" colspan="1" rowspan="1">0.78 (0.41, 1.50)</td><td align="left" colspan="1" rowspan="1">0.456</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Other/unknown</td><td align="left" colspan="1" rowspan="1">11 (11.1)</td><td align="left" colspan="1" rowspan="1">0.99 (0.52, 1.89)</td><td align="left" colspan="1" rowspan="1">0.971</td><td align="left" colspan="1" rowspan="1">5 (45.5)</td><td align="left" colspan="1" rowspan="1">0.73 (0.21, 2.55)</td><td align="left" colspan="1" rowspan="1">0.625</td><td align="left" colspan="1" rowspan="1">3 (27.3)</td><td align="left" colspan="1" rowspan="1">0.68 (0.17, 2.69)</td><td align="left" colspan="1" rowspan="1">0.581</td></tr><tr><td align="left" colspan="1" rowspan="1">Smoking Status</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Never</td><td align="left" colspan="1" rowspan="1">47 (5.6)</td><td align="left" colspan="1" rowspan="1">ref</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">15 (31.9)</td><td align="left" colspan="1" rowspan="1">ref</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">11 (23.4)</td><td align="left" colspan="1" rowspan="1">ref</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Current</td><td align="left" colspan="1" rowspan="1">533 (8.5)</td><td align="left" colspan="1" rowspan="1">1.70 (1.24, 2.32)</td><td align="left" colspan="1" rowspan="1">0.001</td><td align="left" colspan="1" rowspan="1">229 (43.0)</td><td align="left" colspan="1" rowspan="1">1.88 (0.97, 3.64)</td><td align="left" colspan="1" rowspan="1">0.059</td><td align="left" colspan="1" rowspan="1">153 (28.7)</td><td align="left" colspan="1" rowspan="1">1.38 (0.67, 2.85)</td><td align="left" colspan="1" rowspan="1">0.378</td></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Past</td><td align="left" colspan="1" rowspan="1">54 (7.2)</td><td align="left" colspan="1" rowspan="1">1.44 (0.96, 2.17)</td><td align="left" colspan="1" rowspan="1">0.081</td><td align="left" colspan="1" rowspan="1">31 (57.4)</td><td align="left" colspan="1" rowspan="1">3.18 (1.37, 7.37)</td><td align="left" colspan="1" rowspan="1">0.007</td><td align="left" colspan="1" rowspan="1">20 (37.0)</td><td align="left" colspan="1" rowspan="1">1.94 (0.79, 4.74)</td><td align="left" colspan="1" rowspan="1">0.148</td></tr><tr><td align="left" colspan="1" rowspan="1">HIV</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;No</td><td align="left" colspan="1" rowspan="1">427 (8.3)</td><td align="left" colspan="1" rowspan="1">ref</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">190 (44.5)</td><td align="left" colspan="1" rowspan="1">ref</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">125 (29.3)</td><td align="left" colspan="1" rowspan="1">ref</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">&#8195;Yes</td><td align="left" colspan="1" rowspan="1">208 (7.7)</td><td align="left" colspan="1" rowspan="1">0.96 (0.75, 1.22)</td><td align="left" colspan="1" rowspan="1">0.724</td><td align="left" colspan="1" rowspan="1">85 (40.9)</td><td align="left" colspan="1" rowspan="1">1.11 (0.69, 1.79)</td><td align="left" colspan="1" rowspan="1">0.653</td><td align="left" colspan="1" rowspan="1">59 (28.4)</td><td align="left" colspan="1" rowspan="1">1.15 (0.69, 1.90)</td><td align="left" colspan="1" rowspan="1">0.597</td></tr><tr><td align="left" colspan="1" rowspan="1">HIV # Class Membership</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">HIV*(Few Co-occurring Diagnoses)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">ref</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">ref</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">ref</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">HIV*(Multiple Pain Conditions)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1.17 (0.75, 1.83)</td><td align="left" colspan="1" rowspan="1">0.485</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.58 (0.24, 1.42)</td><td align="left" colspan="1" rowspan="1">0.234</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.53 (0.19, 1.47)</td><td align="left" colspan="1" rowspan="1">0.224</td></tr><tr><td align="left" colspan="1" rowspan="1">HIV*(Pain&#8201;+&#8201;SUD)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.77 (0.41, 1.43)</td><td align="left" colspan="1" rowspan="1">0.404</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.87 (0.25, 3.11)</td><td align="left" colspan="1" rowspan="1">0.837</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1.26 (0.33, 4.86)</td><td align="left" colspan="1" rowspan="1">0.735</td></tr><tr><td align="left" colspan="1" rowspan="1">HIV*(Pain&#8201;+&#8201;SUD&#8201;+&#8201;Mental Health)</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">1.10 (0.67, 1.83)</td><td align="left" colspan="1" rowspan="1">0.699</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.54 (0.20, 1.49)</td><td align="left" colspan="1" rowspan="1">0.235</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1">0.88 (0.30, 2.62)</td><td align="left" colspan="1" rowspan="1">0.819</td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Of the 7,875 patients with an index OUD behavior treatment visit during the study period, 635 (8.1%) initiated buprenorphine in the year following the index visit. Among those who initiated buprenorphine, 275 (43.3%) and 184 (29.0%) were retained at six and 12 months, respectively</p></table-wrap-foot></table-wrap>
</p><p id="Par16">A plurality of the OUD sample belonged to the &#8220;Few Co-occurring Diagnoses&#8221; class (42.3%). This class was characterized by a low prevalence of pain, mental health, and SUD diagnoses. Only a quarter of patients had a diagnosis of limb/extremity, joint, or arthritic pain (25.9%), and neuropathic pain was rare (2.0%). The proportion of class members with mental health diagnoses was the lowest of any group, with comparatively low rates of bipolar disorder (5.4%), schizophrenia (6.4%), anxiety disorder (6.5%), and major depressive disorder (9.4%). While nearly a third of patients had a diagnosis of alcohol use disorder (28.7%), other non-opioid SUDs were less common, including cocaine use disorder (5.4%) and cannabis use disorder (1.1%).</p><p id="Par17">The second largest class (&#8220;Multiple Pain Conditions&#8221; class; 21.3%) was characterized by a high frequency of pain and pain diagnoses, but a generally low frequency of SUDs and other comorbidities. Over two-thirds of patients (66.9%) reported moderate to severe intensity pain closest to the index OUD encounter, and limb/extremity, joint, or arthritic (78.5%) and neuropathic (59.7%) pain diagnoses were present in a majority of class members. Though rates of mental health diagnoses were higher than in the &#8220;Few Co-occurring Diagnoses&#8221; class, only &#8220;other depression&#8221; was present in most patients (55.7%), and no single predominant mental health diagnosis emerged among members in this class.</p><p id="Par18">The third class, coined the &#8220;Pain&#8201;+&#8201;SUD&#8221; class (18.4%), was characterized by higher levels of limb/extremity, joint, or arthritic (45.5%) pain as well as SUDs. Cocaine use disorder was present in almost all class members (96.2%), with most also having alcohol use disorder (83.3%) and over a third having cannabis use disorder (36.6%). The prevalence of mental health disorders was lower relative to the &#8220;Pain&#8201;+&#8201;SUD&#8201;+&#8201;Mental Health&#8221; class, with the notable exception of schizophrenia (20.4%), which was the highest for any class.</p><p id="Par19">Finally, the smallest class the &#8220;Pain&#8201;+&#8201;SUD&#8201;+&#8201;Mental Health&#8221; class (18.0%), was characterized by a high prevalence of co-occurring conditions in all three areas. Limb/extremity, joint, or arthritic pain (62.5%) was common, and over a quarter of patients had neuropathic pain diagnoses (25.3%). The prevalence of alcohol use disorder (87.9%) was the highest of any class, with significant proportions of patients also having cocaine (65.8%) and/or cannabis (40.8%) use disorders. The less common SUDs, including amphetamine (16.2%), sedative (9.0%), and hallucinogen (1.4%) use disorders, were prevalent in this class. Further, a majority of class members had diagnoses of other depression (87.2%) and major depressive disorder (65.1%). Almost half of class members had anxiety disorder (45.7%) and post-traumatic stress disorder (47.8%).</p></sec><sec id="Sec10"><title>Patient Characteristics by Class Membership</title><p id="Par20">Nearly every patient characteristic significantly varied by class membership (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>). Patients in the &#8220;Pain&#8201;+&#8201;SUD&#8201;+&#8201;Mental Health&#8221; class had the lowest average age (52.9 years). The &#8220;Multiple Pain Conditions&#8221; class was disproportionately White (47.2%), while Black patients were overrepresented in the &#8220;Pain&#8201;+&#8201;SUD&#8221; class (78.1%). Current smoking was most common in the &#8220;Pain&#8201;+&#8201;SUD&#8221; class (86.3%), while past smoking was most common in the &#8220;Multiple Pain Conditions&#8221; class (14.3%). Only a quarter of patients in the &#8220;Multiple Pain Conditions&#8221; class had a HIV diagnosis (24.9%), compared with 34.1 &#8722;&#8201;39.1% of other classes. Among PWH, antiretroviral use varied across classes before (62.6 &#8722;&#8201;77.1%, &#935;<sup>2</sup>&#8201;=&#8201;64.81, <italic toggle="yes">p</italic>&#8201;&lt;&#8201;0.001) and after OUD diagnosis (75.0 &#8722;&#8201;81.6%, &#935;<sup>2</sup>&#8201;=&#8201;12.96, <italic toggle="yes">p</italic>&#8201;=&#8201;0.005), with the lowest antiretroviral use in the &#8220;Few Co-occurring Diagnoses&#8221; class (62.6% and 75.0%, respectively).</p></sec><sec id="Sec11"><title>Overall Treatment Initiation and Retention</title><p id="Par21">Fewer than one in ten (8.1%, <italic toggle="yes">n</italic>&#8201;=&#8201;635) patients with a new OUD clinical encounter initiated buprenorphine in the year following the index visit. The rate of buprenorphine initiation did not vary between PWH (7.7%) and PWoH (8.3%, &#935;<sup>2</sup>&#8201;=&#8201;0.741, <italic toggle="yes">p</italic>&#8201;=&#8201;0.389). Among patients who initiated buprenorphine, 43.3% and 29.0% were retained at six and 12 months, respectively, with no differences by HIV status.</p></sec><sec id="Sec12"><title>Multivariable Regression of Class Membership and Buprenorphine Outcomes</title><p id="Par22">In the multivariable regression analysis, patients in the two classes with the highest prevalence of co-occurring disorders, the &#8220;Pain&#8201;+&#8201;SUD&#8221; class and the &#8220;Pain&#8201;+&#8201;SUD&#8201;+&#8201;Mental Health&#8221; class, were significantly less likely to initiate buprenorphine within one year of the index OUD encounter. Specifically, compared to members of the &#8220;Few Co-occurring Diagnoses&#8221; class, those in the &#8220;Pain&#8201;+&#8201;SUD&#8221; and &#8220;Pain&#8201;+&#8201;SUD&#8201;+&#8201;Mental Health&#8221; classes had 59% (aOR: 0.41; 95% CI: 0.28, 0.59) and 45% (aOR: 0.55; 95% CI: 0.41, 0.75) lower odds, respectively, of initiating buprenorphine (Table&#160;<xref rid="Tab4" ref-type="table">4</xref>). Further, after controlling for pain, SUDs, and mental health conditions, Black patients were significantly less likely (aOR: 0.72; 95% CI: 0.60, 0.86) to initiate buprenorphine, while individuals who were documented as currently smoking had 70% higher odds of starting treatment (aOR: 1.70; 95% CI: 1.24, 2.32). Older patients were less likely, albeit by only 3%, to initiate buprenorphine than younger patients (aOR: 0.97; 95% CI: 0.96, 0.98). The association of class membership with buprenorphine initiation did not vary by HIV status.</p><p id="Par23">Among study participants who initiated buprenorphine, class membership and age were not associated with retention in buprenorphine treatment at six or 12 months. Racial differences in retention were evident in multivariable analysis, with Black patients being approximately half as likely to remain in treatment at six months (aOR: 0.48, 95% CI: 0.34, 0.69) and 12 months (aOR: 0.53, 95% CI: 0.37, 0.78). Those reporting past smoking had significantly higher odds of six month (aOR: 3.18; 95% CI: 1.37, 7.37) but not 12 month retention (aOR: 1.94, 95% CI: 0.79, 4.74). As with buprenorphine initiation, neither HIV status nor the interaction of HIV status and class membership were significantly associated with treatment retention (Table&#160;<xref rid="Tab4" ref-type="table">4</xref>).</p></sec></sec><sec id="Sec13" sec-type="discussion"><title>Discussion</title><p id="Par24">This study used LCA to identify four subgroups of patients with OUD based on patterns of co-occurring pain, non-opioid SUDs, and mental health diagnoses. While the largest class was characterized by low prevalence of diagnoses in all three areas (i.e., &#8220;Few Co-occurring Diagnoses&#8221; class), other identified classes had higher frequencies of co-occurring diagnoses, including pain alone (i.e., &#8220;Multiple Pain Conditions&#8221; class) or pain in combination with non-opioid SUDs (i.e., &#8220;Pain&#8201;+&#8201;SUD&#8221; class) with or without mental health conditions (i.e., &#8220;Pain&#8201;+&#8201;SUD&#8201;+&#8201;Mental Health&#8221; class). PWH were less likely to present with pain alone and either presented with no conditions or multiple conditions (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>).</p><p id="Par25">In multivariable models, patients in the &#8220;Pain&#8201;+&#8201;SUD&#8221; and &#8220;Pain&#8201;+&#8201;SUD&#8201;+&#8201;Mental Health&#8221; classes, were less likely to initiate buprenorphine than patients in the &#8220;Few Co-occurring Diagnoses&#8221; group. There was no difference in buprenorphine initiation between patients in the &#8220;Multiple Pain Conditions&#8221; and &#8220;Few Co-occurring Diagnoses&#8221; class. Patients in the &#8220;Pain&#8201;+&#8201;SUD&#8201;+&#8201;Mental Health&#8221; class were characterized by a high prevalence of major depressive disorder, anxiety disorder, and/or post-traumatic stress disorder whereas patients in the &#8220;Pain&#8201;+&#8201;SUD&#8221; class had a much lower incidence of mental health conditions. These findings are consistent with several other studies reporting that patients with a mental health condition are less likely to initiate opioid agonist treatment [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. However, not all studies have come to the same conclusions [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. These disparate findings may be due to differencs in study designs. Interestingly, the odds of initiating buprenorphine was numerically larger in the &#8220;Pain&#8201;+&#8201;SUD&#8201;+&#8201;Mental Health&#8221; class as compared to the &#8220;Pain&#8201;+&#8201;SUD&#8221; class when compared to the &#8220;Few Co-occuring Diagnoses&#8221; class. This could suggest that a mental health diagnosis in some regard may positively influence treatment initiation. To explore this outcome, we changed the reference class in the regression model to the &#8220;Pain&#8201;+&#8201;SUD&#8221; class. In this model both the &#8220;Few Co-occurring Diagnoses&#8221; class and &#8220;Multiple Pain Conditions&#8221; class remained more likely to initiate treatment than the &#8220;Pain&#8201;+&#8201;SUD&#8221; class. However, the difference in the odds of buprenorphine initiation within the &#8220;Pain&#8201;+&#8201;SUD&#8201;+&#8201;Mental Health&#8221; class and the &#8220;Pain&#8201;+&#8201;SUD&#8221; class was not statistically significant (aOR: 1.35; 95% CI: 0.88, 2.07).</p><p id="Par26">Overall, the findings from this study suggest that SUD and/or mental health diagnoses may have a negative impact on buprenorphine initiation in the setting of co-occurring pain diagnoses. Others have noted that people with OUD and co-occurring mental health conditions require comprehensive care and lack of this may create access barriers to OUD treatment [<xref ref-type="bibr" rid="CR48">48</xref>]. Additionally, a lack of mental health support is a commonly cited barrier to buprenorphine prescribing among buprenorphine-waivered physicians [<xref ref-type="bibr" rid="CR49">49</xref>, <xref ref-type="bibr" rid="CR50">50</xref>]. A systems-level approach to coordinating care and expanding mental health resources for patients with co-occurring OUD, mental health conditions, pain, and/or non-opioid SUD diagnoses may improve prescribers&#8217; ability to initiate buprenorphine in these complex patients. Additional research on the impact of expanding buprenorphine access through telehealth during the COVID-19 pandemic may inform future efforts to reduce barriers to buprenorphine initiation among patients with many co-occurring diagnoses.</p><p id="Par27">Retention in buprenorphine treatment at six and 12 months did not vary by class membership, HIV status, or their interaction in the multivariable analysis. This finding adds to a growing body of literature reporting a lack of association between mental health [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR51">51</xref>] or pain diagnoses [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR38">38</xref>] and buprenorphine retention. In contrast to previous research which has consistently reported an association between co-occurring SUDs and lower odds of OUD treatment retention, the present study did not find an association between membership in the classes of high SUD prevalence and retention [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR38">38</xref>, <xref ref-type="bibr" rid="CR51">51</xref>&#8211;<xref ref-type="bibr" rid="CR53">53</xref>]. Notably, other studies have rarely controlled for mental health and/or pain diagnoses, which are relevant confounders given that patients with both OUD and pain have higher rates of co-occurring SUD and mental health conditions [<xref ref-type="bibr" rid="CR54">54</xref>]. The lack of association between class membership and buprenorphine retention suggests that other buprenorphine-related and contextual factors not included in this analysis, including setting of initiation [<xref ref-type="bibr" rid="CR55">55</xref>], initial and ongoing buprenorphine dosing [<xref ref-type="bibr" rid="CR55">55</xref>], buprenorphine out-of-pocket costs [<xref ref-type="bibr" rid="CR56">56</xref>], and provider-level requirements for ongoing care [<xref ref-type="bibr" rid="CR57">57</xref>], may contribute more substantially to buprenorphine retention than a patient&#8217;s overall physical and mental health. Clinical efforts to optimize dosing and clinic requirements during ongoing treatments, combined with policy-level efforts to reduce barriers, including cost, may improve buprenorphine retention among patients with diverse co-occurring diagnoses.</p><p id="Par28">We also found that Black patients were significantly less likely to initiate and continue buprenorphine treatment than their White counterparts, consistent with treatment disparities reported in Medicaid [<xref ref-type="bibr" rid="CR51">51</xref>, <xref ref-type="bibr" rid="CR58">58</xref>], VHA [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR59">59</xref>], and primary care populations [<xref ref-type="bibr" rid="CR60">60</xref>&#8211;<xref ref-type="bibr" rid="CR62">62</xref>]. Our study did not include factors associated with buprenorphine retention, such as distance to treatment, housing, transportation or provider, peer, and social support [<xref ref-type="bibr" rid="CR51">51</xref>], which may have been important covariates, and which could explain this association. Future research is needed to better understand patient-, provider-, and system-level factors that may contribute to the observed racial disparities in buprenorphine treatment engagement, especially given the disproportionate impact of the COVID-19 pandemic among Black patients [<xref ref-type="bibr" rid="CR63">63</xref>]. Older patients were also less likely to initiate buprenorphine. This disparity has been previously observed in the literature and may be due to unique needs of older adults such as mobility, access to health services, and stigma [<xref ref-type="bibr" rid="CR64">64</xref>, <xref ref-type="bibr" rid="CR65">65</xref>].</p><p id="Par29">This study had several limitations. First, this study focused on opioid agonist therapy, specifically buprenorphine, and did not include methadone, a common methodological decision given that buprenorphine can be prescribed in office-based settings [<xref ref-type="bibr" rid="CR51">51</xref>&#8211;<xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR58">58</xref>, <xref ref-type="bibr" rid="CR60">60</xref>, <xref ref-type="bibr" rid="CR62">62</xref>]. This approach precluded an analysis of overall opioid agonist therapy engagement or the identification of patients who switched from buprenorphine to methadone, although by 2017 the majority of Veterans treated with a medication for OUD were utilizing buprenorphine [<xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. Future research is needed to understand whether patterns of comorbidity differentially impact receipt of, and retention on, buprenorphine and methadone. Second, consistent with past research in this study population [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR40">40</xref>], SUDs were identified using ICD codes, which have high specificity, but low sensitivity compared to self-reported drug use [<xref ref-type="bibr" rid="CR66">66</xref>]. The prevalence of co-occurring SUDs in this study may therefore be underestimated. However, the inclusion of SUD comorbidities considerably strengthened measures of LCA model adequacy. Third, mental health medications or behavioral treatments were not included as covariates. While this limitation is common in buprenorphine retention literature [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR53">53</xref>, <xref ref-type="bibr" rid="CR61">61</xref>], and the effect of mental health treatment was not found to be significant in a prior study [<xref ref-type="bibr" rid="CR51">51</xref>], adequate treatment of co-occurring conditions may impact patient engagement with their OUD treatment. Fourth, the study population consisted primarily of older Black men who received OUD behavioral treatment within the VHA population, which may limit the generalizability. Finally, this study did not include contextual variables, including location of residence, homelessness, or social support, nor unmeasured confounders such as OUD severity, that may impact treatment initiation and retention.</p></sec><sec id="Sec14" sec-type="conclusion"><title>Conclusion</title><p id="Par30">Our results demonstrate heterogeneity in the comorbidity burden of Veterans with OUD. Patients in the two subgroups with the highest comorbidity burden, the &#8220;Pain&#8201;+&#8201;SUD&#8221; and &#8220;Pain&#8201;+&#8201;SUD&#8201;+&#8201;Mental Health&#8221; classes, were significantly less likely to initiate buprenorphine than those in the &#8220;Few Co-occurring Diagnoses&#8221; class. However, among patients who started buprenorphine treatment, patterns of comorbidities were not associated with treatment retention. Other elements, such as systemic and structural factors around race and/or discrimination, may have a greater effect on treatment retention. Future studies are needed to build further understanding of the potential effects of combined co-occurring conditions on OUD-related outcomes.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="author-contribution"><title>Author Contributions</title><p>Data for this study were obtained from the Veterans Aging Cohort Study (VACS). Study design and literature review were completed by Emily A. Miller, Kathleen A. McGinnis, E. Jennifer Edelman, Julie A. Patterson, and MaryPeace McRae. Kathleen A. McGinnis and Julie A. Patterson led data cleaning, analysis, and interpretation. Emily A. Miller, Julie A. Patterson, and MaryPeace McRae led manuscript writing. Kathleen A. McGinnis, Julie A. Patterson, and MaryPeace McRae provided mentorship throughout the writing process. All authors contributed to manuscript editing and refinement. The final manuscript has been approved by all authors.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was supported by the National Institute on Alcohol Abuse and Alcoholism U10 <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="AA013566">AA013566</ext-link>, U24 <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="AA020794">AA020794</ext-link>, U01 <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="AA020790">AA020790</ext-link>; and by the National Institute on Drug Abuse R01 DA053153. The content of this article is solely the responsibility of the authors and does not represent the official views of the U.S. Government or the Department of Veterans Affairs or the National Institute on Alcohol Abuse and Alcoholism or the National Institute on Drug Abuse.</p></notes><notes notes-type="data-availability"><title>Data Availability</title><p>The data utilized in this study were derived from the Veterans Aging Cohort Study (VACS) which maintains electronic health record (EHR) from the Veterans Health Administration (VHA). Data is available upon request and proposal approval through the VA Family of EHR Cohorts (VACo Family) website.</p></notes><notes><title>Declarations</title><notes id="FPar2" notes-type="COI-statement"><title>Competing Interests</title><p id="Par35">Termeh Feinberg was supported as a contractor with the National Institutes of Health National Center for Complementary and Integrative Health. All other authors declare no potential conflicts of interest. Preliminary findings of this research study were presented at the American Society of Clinical Pharmacology and Therapeutics (ASCPT) Annual Meeting in Atlanta, GA in March 2023.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mimiaga</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Reisner</surname><given-names>SL</given-names></name><name name-style="western"><surname>Grasso</surname><given-names>C</given-names></name><name name-style="western"><surname>Crane</surname><given-names>HM</given-names></name><name name-style="western"><surname>Safren</surname><given-names>SA</given-names></name><name name-style="western"><surname>Kitahata</surname><given-names>MM</given-names></name><etal/></person-group><article-title>Substance use among HIV-infected patients engaged in primary care in the United States: findings from the Centers for AIDS Research Network of Integrated Clinical Systems cohort</article-title><source>Am J Public Health</source><year>2013</year><volume>103</volume><fpage>1457</fpage><lpage>67</lpage><pub-id pub-id-type="doi">10.2105/AJPH.2012.301162</pub-id><pub-id pub-id-type="pmid">23763417</pub-id><pub-id pub-id-type="pmcid">PMC3752382</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Mimiaga MJ, Reisner SL, Grasso C, Crane HM, Safren SA, Kitahata MM, et al. Substance use among HIV-infected patients engaged in primary care in the United States: findings from the Centers for AIDS Research Network of Integrated Clinical Systems cohort. Am J Public Health. 2013;103:1457&#8211;67.<pub-id pub-id-type="pmid">23763417</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2105/AJPH.2012.301162</pub-id><pub-id pub-id-type="pmcid">PMC3752382</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">Lapham G, Boudreau DM, Johnson EA, Bobb JF, Matthews AG, McCormack J et al. Prevalence and treatment of opioid use disorders among primary care patients in six health systems. Drug Alcohol Depend. 2020;207.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drugalcdep.2019.107732</pub-id><pub-id pub-id-type="pmcid">PMC7158756</pub-id><pub-id pub-id-type="pmid">31835068</pub-id></mixed-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">Parker MA, Weinberger AH. Opioid Use Disorder Trends from 2002 to 2017 by Cigarette Smoking Status in the United States. Nicotine Tob Res. 2021;1405&#8211;9.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ntr/ntaa189</pub-id><pub-id pub-id-type="pmid">32960266</pub-id></mixed-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="other">Hartzler B, Dombrowski JC, Crane HM, Eron JJ, Geng EH, Mathews W et al. Prevalence and predictors of substance use disorders among HIV care enrollees in the United States. AIDS Behav. 2017;21.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10461-016-1584-6</pub-id><pub-id pub-id-type="pmcid">PMC6089366</pub-id><pub-id pub-id-type="pmid">27738780</pub-id></mixed-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="other">Buresh M, Stern R, Rastegar D. Treatment of opioid use disorder in primary care. BMJ. 2021;373.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.n784</pub-id><pub-id pub-id-type="pmid">34011512</pub-id></mixed-citation></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fanucchi</surname><given-names>L</given-names></name><name name-style="western"><surname>Springer</surname><given-names>SA</given-names></name><name name-style="western"><surname>Korthuis</surname><given-names>PT</given-names></name></person-group><article-title>Medications for treatment of opioid use disorder among persons living with HIV</article-title><source>Curr HIV/AIDS Rep</source><year>2019</year><volume>16</volume><fpage>1</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1007/s11904-019-00436-7</pub-id><pub-id pub-id-type="pmid">30684117</pub-id><pub-id pub-id-type="pmcid">PMC6420833</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Fanucchi L, Springer SA, Korthuis PT. Medications for treatment of opioid use disorder among persons living with HIV. Curr HIV/AIDS Rep. 2019;16:1&#8211;6.<pub-id pub-id-type="pmid">30684117</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s11904-019-00436-7</pub-id><pub-id pub-id-type="pmcid">PMC6420833</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wyse</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Robbins</surname><given-names>JL</given-names></name><name name-style="western"><surname>McGinnis</surname><given-names>KA</given-names></name><name name-style="western"><surname>Edelman</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Manhapra</surname><given-names>A</given-names></name><etal/></person-group><article-title>Predictors of timely opioid agonist treatment initiation among veterans with and without HIV</article-title><source>Drug Alcohol Depend</source><year>2019</year><volume>198</volume><fpage>70</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1016/j.drugalcdep.2019.01.038</pub-id><pub-id pub-id-type="pmid">30878769</pub-id><pub-id pub-id-type="pmcid">PMC6836871</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Wyse JJ, Robbins JL, McGinnis KA, Edelman EJ, Gordon AJ, Manhapra A, et al. Predictors of timely opioid agonist treatment initiation among veterans with and without HIV. Drug Alcohol Depend. 2019;198:70&#8211;5.<pub-id pub-id-type="pmid">30878769</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drugalcdep.2019.01.038</pub-id><pub-id pub-id-type="pmcid">PMC6836871</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kraemer</surname><given-names>KL</given-names></name><name name-style="western"><surname>McGinnis</surname><given-names>KA</given-names></name><name name-style="western"><surname>Fiellin</surname><given-names>DA</given-names></name><name name-style="western"><surname>Skanderson</surname><given-names>M</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Robbins</surname><given-names>J</given-names></name><etal/></person-group><article-title>Low levels of initiation, engagement, and retention in substance use disorder treatment including pharmacotherapy among HIV-infected and uninfected veterans</article-title><source>J Subst Abuse Treat</source><year>2019</year><volume>103</volume><fpage>23</fpage><lpage>32</lpage><pub-id pub-id-type="doi">10.1016/j.jsat.2019.05.007</pub-id><pub-id pub-id-type="pmid">31229189</pub-id><pub-id pub-id-type="pmcid">PMC6815097</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Kraemer KL, McGinnis KA, Fiellin DA, Skanderson M, Gordon AJ, Robbins J, et al. Low levels of initiation, engagement, and retention in substance use disorder treatment including pharmacotherapy among HIV-infected and uninfected veterans. J Subst Abuse Treat. 2019;103:23&#8211;32.<pub-id pub-id-type="pmid">31229189</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jsat.2019.05.007</pub-id><pub-id pub-id-type="pmcid">PMC6815097</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lin</surname><given-names>LA</given-names></name><name name-style="western"><surname>Bohnert</surname><given-names>ASB</given-names></name><name name-style="western"><surname>Blow</surname><given-names>FC</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Ignacio</surname><given-names>RV</given-names></name><name name-style="western"><surname>Kim</surname><given-names>HM</given-names></name><etal/></person-group><article-title>Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration</article-title><source>Addiction</source><year>2021</year><volume>116</volume><fpage>96</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1111/add.15116</pub-id><pub-id pub-id-type="pmid">32428386</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Lin LA, Bohnert ASB, Blow FC, Gordon AJ, Ignacio RV, Kim HM, et al. Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration. Addiction. 2021;116:96&#8211;104.<pub-id pub-id-type="pmid">32428386</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/add.15116</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Scherrer</surname><given-names>JF</given-names></name><name name-style="western"><surname>Salas</surname><given-names>J</given-names></name><name name-style="western"><surname>Grucza</surname><given-names>R</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>MD</given-names></name><name name-style="western"><surname>Lustman</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Copeland</surname><given-names>LA</given-names></name><etal/></person-group><article-title>Depression and Buprenorphine Treatment in patients with Non-cancer Pain and prescription opioid dependence without Comorbid Substance Use disorders</article-title><source>J Affect Disord</source><year>2021</year><volume>278</volume><fpage>563</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2020.09.089</pub-id><pub-id pub-id-type="pmid">33022442</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Scherrer JF, Salas J, Grucza R, Sullivan MD, Lustman PJ, Copeland LA, et al. Depression and buprenorphine treatment in patients with non-cancer pain and prescription opioid dependence without comorbid substance use disorders. J Affect Disord. 2021;278:563&#8211;9.<pub-id pub-id-type="pmid">33022442</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jad.2020.09.089</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shiner</surname><given-names>B</given-names></name><name name-style="western"><surname>Westgate</surname><given-names>CL</given-names></name><name name-style="western"><surname>Bernardy</surname><given-names>NC</given-names></name><name name-style="western"><surname>Schnurr</surname><given-names>PP</given-names></name><name name-style="western"><surname>Watts</surname><given-names>BV</given-names></name></person-group><article-title>Trends in Opioid Use Disorder diagnoses and Medication Treatment among veterans with posttraumatic stress disorder</article-title><source>J Dual Diagn</source><year>2017</year><volume>13</volume><fpage>201</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1080/15504263.2017.1325033</pub-id><pub-id pub-id-type="pmid">28481727</pub-id><pub-id pub-id-type="pmcid">PMC6190703</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Shiner B, Westgate CL, Bernardy NC, Schnurr PP, Watts BV. Trends in opioid use disorder diagnoses and medication treatment among veterans with posttraumatic stress disorder. J Dual Diagn. 2017;13:201&#8211;12.<pub-id pub-id-type="pmid">28481727</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/15504263.2017.1325033</pub-id><pub-id pub-id-type="pmcid">PMC6190703</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>S</given-names></name><name name-style="western"><surname>Yerneni</surname><given-names>R</given-names></name><name name-style="western"><surname>Healy</surname><given-names>S</given-names></name><name name-style="western"><surname>Goyal</surname><given-names>M</given-names></name><name name-style="western"><surname>Neighbors</surname><given-names>CJ</given-names></name></person-group><article-title>Predictors of medication utilization for opioid Use Disorder among Medicaid-Insured HIV patients in New York</article-title><source>Am J Addict</source><year>2020</year><volume>29</volume><fpage>151</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1111/ajad.12998</pub-id><pub-id pub-id-type="pmid">31951083</pub-id><pub-id pub-id-type="pmcid">PMC7035191</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Choi S, Yerneni R, Healy S, Goyal M, Neighbors CJ. Predictors of medication utilization for opioid use disorder among Medicaid-insured HIV patients in New York. Am J Addict. 2020;29:151&#8211;4.<pub-id pub-id-type="pmid">31951083</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ajad.12998</pub-id><pub-id pub-id-type="pmcid">PMC7035191</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manhapra</surname><given-names>A</given-names></name><name name-style="western"><surname>Stefanovics</surname><given-names>E</given-names></name><name name-style="western"><surname>Rosenheck</surname><given-names>R</given-names></name></person-group><article-title>Initiating opioid agonist treatment for opioid use disorder nationally in the Veterans Health Administration: who gets what?</article-title><source>Subst Abus</source><year>2020</year><volume>41</volume><fpage>110</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1080/08897077.2019.1640831</pub-id><pub-id pub-id-type="pmid">31403914</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Manhapra A, Stefanovics E, Rosenheck R. Initiating opioid agonist treatment for opioid use disorder nationally in the Veterans Health Administration: who gets what? Subst Abus. 2020;41:110&#8211;20.<pub-id pub-id-type="pmid">31403914</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/08897077.2019.1640831</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wyse</surname><given-names>JJ</given-names></name><name name-style="western"><surname>McGinnis</surname><given-names>KA</given-names></name><name name-style="western"><surname>Jennifer Edelman</surname><given-names>E</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Manhapra</surname><given-names>A</given-names></name><name name-style="western"><surname>Fiellin</surname><given-names>DA</given-names></name><etal/></person-group><article-title>Twelve-Month Retention in Opioid Agonist Treatment for Opioid Use Disorder among patients with and without HIV</article-title><source>AIDS Behav</source><year>2021</year><volume>1</volume><fpage>3</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10461-021-03452-0</pub-id><pub-id pub-id-type="pmcid">PMC8840957</pub-id><pub-id pub-id-type="pmid">34495424</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Wyse JJ, McGinnis KA, Jennifer Edelman E, Gordon AJ, Manhapra A, Fiellin DA, et al. Twelve-month retention in opioid agonist treatment for opioid use disorder among patients with and without HIV. AIDS Behav. 2021;1:3.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10461-021-03452-0</pub-id><pub-id pub-id-type="pmcid">PMC8840957</pub-id><pub-id pub-id-type="pmid">34495424</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Donohue</surname><given-names>JM</given-names></name><name name-style="western"><surname>Jarlenski</surname><given-names>MP</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JY</given-names></name><name name-style="western"><surname>Tang</surname><given-names>L</given-names></name><name name-style="western"><surname>Ahrens</surname><given-names>K</given-names></name><name name-style="western"><surname>Allen</surname><given-names>L</given-names></name><etal/></person-group><article-title>Use of medications for Treatment of Opioid Use Disorder among US Medicaid Enrollees in 11 States, 2014&#8211;2018</article-title><source>JAMA</source><year>2021</year><volume>326</volume><fpage>154</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1001/jama.2021.7374</pub-id><pub-id pub-id-type="pmid">34255008</pub-id><pub-id pub-id-type="pmcid">PMC8278273</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Donohue JM, Jarlenski MP, Kim JY, Tang L, Ahrens K, Allen L, et al. Use of medications for treatment of opioid use disorder among US Medicaid enrollees in 11 states, 2014&#8211;2018. JAMA. 2021;326:154&#8211;64.<pub-id pub-id-type="pmid">34255008</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2021.7374</pub-id><pub-id pub-id-type="pmcid">PMC8278273</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manhapra</surname><given-names>A</given-names></name><name name-style="western"><surname>Petrakis</surname><given-names>I</given-names></name><name name-style="western"><surname>Rosenheck</surname><given-names>R</given-names></name></person-group><article-title>Three-year retention in buprenorphine treatment for opioid use disorder nationally in the Veterans Health Administration</article-title><source>Am J Addict</source><year>2017</year><volume>26</volume><fpage>572</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1111/ajad.12553</pub-id><pub-id pub-id-type="pmid">28472543</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Manhapra A, Petrakis I, Rosenheck R. Three-year retention in buprenorphine treatment for opioid use disorder nationally in the Veterans Health Administration. Am J Addict. 2017;26:572&#8211;80.<pub-id pub-id-type="pmid">28472543</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ajad.12553</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maclean</surname><given-names>RR</given-names></name><name name-style="western"><surname>Spinola</surname><given-names>S</given-names></name><name name-style="western"><surname>Manhapra</surname><given-names>A</given-names></name><name name-style="western"><surname>Sofuoglu</surname><given-names>M</given-names></name></person-group><article-title>Systematic review of Pain Severity and opioid craving in Chronic Pain and Opioid Use Disorder</article-title><source>Pain Med</source><year>2020</year><volume>21</volume><fpage>e146</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">32034413</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/pm/pnz228</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Maclean RR, Spinola S, Manhapra A, Sofuoglu M. Systematic review of pain severity and opioid craving in chronic pain and opioid use disorder. Pain Med. 2020;21:e146&#8211;63.<pub-id pub-id-type="pmid">32034413</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/pm/pnz228</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Panlilio</surname><given-names>LV</given-names></name><name name-style="western"><surname>Stull</surname><given-names>SW</given-names></name><name name-style="western"><surname>Kowalczyk</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>KA</given-names></name><name name-style="western"><surname>Schroeder</surname><given-names>JR</given-names></name><name name-style="western"><surname>Bertz</surname><given-names>JW</given-names></name><etal/></person-group><article-title>Stress, craving and mood as predictors of early dropout from opioid agonist therapy</article-title><source>Drug Alcohol Depend</source><year>2019</year><volume>202</volume><fpage>200</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.drugalcdep.2019.05.026</pub-id><pub-id pub-id-type="pmid">31357121</pub-id><pub-id pub-id-type="pmcid">PMC6707374</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Panlilio LV, Stull SW, Kowalczyk WJ, Phillips KA, Schroeder JR, Bertz JW, et al. Stress, craving and mood as predictors of early dropout from opioid agonist therapy. Drug Alcohol Depend. 2019;202:200&#8211;8.<pub-id pub-id-type="pmid">31357121</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drugalcdep.2019.05.026</pub-id><pub-id pub-id-type="pmcid">PMC6707374</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">Parker R, Stein DJ, Jelsma J. Pain in people living with HIV/AIDS: a systematic review. J Int AIDS Soc. 2014;17.<pub-id pub-id-type="doi" assigning-authority="pmc">10.7448/IAS.17.1.18719</pub-id><pub-id pub-id-type="pmcid">PMC3929991</pub-id><pub-id pub-id-type="pmid">24560338</pub-id></mixed-citation></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Denis</surname><given-names>CM</given-names></name><name name-style="western"><surname>Morales</surname><given-names>KH</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Q</given-names></name><name name-style="western"><surname>Metzger</surname><given-names>DS</given-names></name><name name-style="western"><surname>Cheatle</surname><given-names>MD</given-names></name></person-group><article-title>Association between diagnoses of Chronic Noncancer Pain, Substance Use Disorder, and HIV-Related outcomes in people living with HIV</article-title><source>J Acquir Immune Defic Syndr</source><year>2019</year><volume>82</volume><issue>Suppl 2</issue><fpage>S142</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1097/QAI.0000000000002179</pub-id><pub-id pub-id-type="pmid">31658202</pub-id><pub-id pub-id-type="pmcid">PMC6822377</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Denis CM, Morales KH, Wu Q, Metzger DS, Cheatle MD. Association between diagnoses of chronic noncancer pain, substance use disorder, and HIV-related outcomes in people living with HIV. J Acquir Immune Defic Syndr. 2019;82(Suppl 2):S142&#8211;7.<pub-id pub-id-type="pmid">31658202</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/QAI.0000000000002179</pub-id><pub-id pub-id-type="pmcid">PMC6822377</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="other">Mee S, Bunney BG, Fujimoto K, Penner J, Seward G, Crowfoot K et al. A study of psychological pain in substance use disorder and its relationship to treatment outcome. PLoS ONE. 2019;14.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0216266</pub-id><pub-id pub-id-type="pmcid">PMC6837512</pub-id><pub-id pub-id-type="pmid">31697679</pub-id></mixed-citation></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jaremko</surname><given-names>KM</given-names></name><name name-style="western"><surname>Sterling</surname><given-names>RC</given-names></name><name name-style="western"><surname>Van Bockstaele</surname><given-names>EJ</given-names></name></person-group><article-title>Psychological and physiological stress negatively impacts early engagement and retention of opioid-dependent individuals on methadone maintenance</article-title><source>J Subst Abuse Treat</source><year>2015</year><volume>48</volume><fpage>117</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1016/j.jsat.2014.08.006</pub-id><pub-id pub-id-type="pmid">25239858</pub-id><pub-id pub-id-type="pmcid">PMC4250337</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Jaremko KM, Sterling RC, Van Bockstaele EJ. Psychological and physiological stress negatively impacts early engagement and retention of opioid-dependent individuals on methadone maintenance. J Subst Abuse Treat. 2015;48:117&#8211;27.<pub-id pub-id-type="pmid">25239858</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jsat.2014.08.006</pub-id><pub-id pub-id-type="pmcid">PMC4250337</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fox</surname><given-names>AD</given-names></name><name name-style="western"><surname>Sohler</surname><given-names>NL</given-names></name><name name-style="western"><surname>Starrels</surname><given-names>JL</given-names></name><name name-style="western"><surname>Ning</surname><given-names>Y</given-names></name><name name-style="western"><surname>Giovanniello</surname><given-names>A</given-names></name><name name-style="western"><surname>Cunningham</surname><given-names>CO</given-names></name></person-group><article-title>Pain is not associated with worse office-based buprenorphine treatment outcomes</article-title><source>Subst Abus</source><year>2012</year><volume>33</volume><fpage>361</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1080/08897077.2011.638734</pub-id><pub-id pub-id-type="pmid">22989279</pub-id><pub-id pub-id-type="pmcid">PMC3447624</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Fox AD, Sohler NL, Starrels JL, Ning Y, Giovanniello A, Cunningham CO. Pain is not associated with worse office-based buprenorphine treatment outcomes. Subst Abus. 2012;33:361&#8211;5.<pub-id pub-id-type="pmid">22989279</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/08897077.2011.638734</pub-id><pub-id pub-id-type="pmcid">PMC3447624</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsai</surname><given-names>J</given-names></name><name name-style="western"><surname>Rosenheck</surname><given-names>RA</given-names></name></person-group><article-title>Psychiatric comorbidity among adults with schizophrenia: a latent class analysis</article-title><source>Psychiatry Res</source><year>2013</year><volume>210</volume><fpage>16</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/j.psychres.2013.05.013</pub-id><pub-id pub-id-type="pmid">23726869</pub-id><pub-id pub-id-type="pmcid">PMC3800495</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Tsai J, Rosenheck RA. Psychiatric comorbidity among adults with schizophrenia: a latent class analysis. Psychiatry Res. 2013;210:16&#8211;20.<pub-id pub-id-type="pmid">23726869</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.psychres.2013.05.013</pub-id><pub-id pub-id-type="pmcid">PMC3800495</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agrawal</surname><given-names>A</given-names></name><name name-style="western"><surname>Lynskey</surname><given-names>MT</given-names></name><name name-style="western"><surname>Madden</surname><given-names>PAF</given-names></name><name name-style="western"><surname>Bucholz</surname><given-names>KK</given-names></name><name name-style="western"><surname>Heath</surname><given-names>AC</given-names></name></person-group><article-title>A latent class analysis of illicit drug abuse/dependence: results from the National Epidemiological Survey on Alcohol and related conditions</article-title><source>Addiction</source><year>2007</year><volume>102</volume><fpage>94</fpage><lpage>104</lpage><pub-id pub-id-type="doi">10.1111/j.1360-0443.2006.01630.x</pub-id><pub-id pub-id-type="pmid">17207127</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Agrawal A, Lynskey MT, Madden PAF, Bucholz KK, Heath AC. A latent class analysis of illicit drug abuse/dependence: results from the National Epidemiological Survey on Alcohol and Related Conditions. Addiction. 2007;102:94&#8211;104.<pub-id pub-id-type="pmid">17207127</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1360-0443.2006.01630.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blow</surname><given-names>FC</given-names></name><name name-style="western"><surname>Walton</surname><given-names>MA</given-names></name><name name-style="western"><surname>Barry</surname><given-names>KL</given-names></name><name name-style="western"><surname>Murray</surname><given-names>RL</given-names></name><name name-style="western"><surname>Cunningham</surname><given-names>RM</given-names></name><name name-style="western"><surname>Massey</surname><given-names>LS</given-names></name><etal/></person-group><article-title>Alcohol and drug use among patients presenting to an inner-city emergency department: a latent class analysis</article-title><source>Addict Behav</source><year>2011</year><volume>36</volume><fpage>793</fpage><lpage>800</lpage><pub-id pub-id-type="doi">10.1016/j.addbeh.2010.12.028</pub-id><pub-id pub-id-type="pmid">21514734</pub-id><pub-id pub-id-type="pmcid">PMC4020511</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Blow FC, Walton MA, Barry KL, Murray RL, Cunningham RM, Massey LS, et al. Alcohol and drug use among patients presenting to an inner-city emergency department: a latent class analysis. Addict Behav. 2011;36:793&#8211;800.<pub-id pub-id-type="pmid">21514734</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.addbeh.2010.12.028</pub-id><pub-id pub-id-type="pmcid">PMC4020511</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Green</surname><given-names>TC</given-names></name><name name-style="western"><surname>Kershaw</surname><given-names>T</given-names></name><name name-style="western"><surname>Lin</surname><given-names>H</given-names></name><name name-style="western"><surname>Heimer</surname><given-names>R</given-names></name><name name-style="western"><surname>Goulet</surname><given-names>JL</given-names></name><name name-style="western"><surname>Kraemer</surname><given-names>KL</given-names></name><etal/></person-group><article-title>Patterns of drug use and abuse among aging adults with and without HIV: a latent class analysis of a US veteran cohort</article-title><source>Drug Alcohol Depend</source><year>2010</year><volume>110</volume><fpage>208</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/j.drugalcdep.2010.02.020</pub-id><pub-id pub-id-type="pmid">20395074</pub-id><pub-id pub-id-type="pmcid">PMC3087206</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Green TC, Kershaw T, Lin H, Heimer R, Goulet JL, Kraemer KL, et al. Patterns of drug use and abuse among aging adults with and without HIV: a latent class analysis of a US Veteran cohort. Drug Alcohol Depend. 2010;110:208&#8211;20.<pub-id pub-id-type="pmid">20395074</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drugalcdep.2010.02.020</pub-id><pub-id pub-id-type="pmcid">PMC3087206</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Parsons</surname><given-names>JT</given-names></name><name name-style="western"><surname>Starks</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Millar</surname><given-names>BM</given-names></name><name name-style="western"><surname>Boonrai</surname><given-names>K</given-names></name><name name-style="western"><surname>Marcotte</surname><given-names>D</given-names></name></person-group><article-title>Patterns of substance use among HIV-positive adults over 50: implications for treatment and medication adherence</article-title><source>Drug Alcohol Depend</source><year>2014</year><volume>139</volume><fpage>33</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/j.drugalcdep.2014.02.704</pub-id><pub-id pub-id-type="pmid">24745475</pub-id><pub-id pub-id-type="pmcid">PMC4028151</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Parsons JT, Starks TJ, Millar BM, Boonrai K, Marcotte D. Patterns of substance use among HIV-positive adults over 50: implications for treatment and medication adherence. Drug Alcohol Depend. 2014;139:33&#8211;40.<pub-id pub-id-type="pmid">24745475</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drugalcdep.2014.02.704</pub-id><pub-id pub-id-type="pmcid">PMC4028151</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weich</surname><given-names>S</given-names></name><name name-style="western"><surname>McBride</surname><given-names>O</given-names></name><name name-style="western"><surname>Hussey</surname><given-names>D</given-names></name><name name-style="western"><surname>Exeter</surname><given-names>D</given-names></name><name name-style="western"><surname>Brugha</surname><given-names>T</given-names></name><name name-style="western"><surname>McManus</surname><given-names>S</given-names></name></person-group><article-title>Latent class analysis of co-morbidity in the Adult Psychiatric Morbidity Survey in England 2007: implications for DSM-5 and ICD-11</article-title><source>Psychol Med</source><year>2011</year><volume>41</volume><fpage>2201</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1017/S0033291711000249</pub-id><pub-id pub-id-type="pmid">21375797</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Weich S, McBride O, Hussey D, Exeter D, Brugha T, McManus S. Latent class analysis of co-morbidity in the Adult Psychiatric Morbidity Survey in England 2007: implications for DSM-5 and ICD-11. Psychol Med. 2011;41:2201&#8211;12.<pub-id pub-id-type="pmid">21375797</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S0033291711000249</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Madkour</surname><given-names>AS</given-names></name><name name-style="western"><surname>Felker-Kantor</surname><given-names>E</given-names></name><name name-style="western"><surname>Wallace</surname><given-names>M</given-names></name><name name-style="western"><surname>Ferguson</surname><given-names>T</given-names></name><name name-style="western"><surname>Welsh</surname><given-names>DA</given-names></name><name name-style="western"><surname>Molina</surname><given-names>PE</given-names></name><etal/></person-group><article-title>Latent Alcohol Use typologies and Health Status among a cohort of adults living with HIV</article-title><source>Alcohol Alcohol</source><year>2019</year><volume>54</volume><fpage>584</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1093/alcalc/agz071</pub-id><pub-id pub-id-type="pmid">31580404</pub-id><pub-id pub-id-type="pmcid">PMC6895462</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Madkour AS, Felker-Kantor E, Wallace M, Ferguson T, Welsh DA, Molina PE, et al. Latent alcohol use typologies and health status among a cohort of adults living with HIV. Alcohol Alcohol. 2019;54:584&#8211;92.<pub-id pub-id-type="pmid">31580404</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/alcalc/agz071</pub-id><pub-id pub-id-type="pmcid">PMC6895462</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramo</surname><given-names>DE</given-names></name><name name-style="western"><surname>Bahorik</surname><given-names>AL</given-names></name><name name-style="western"><surname>Delucchi</surname><given-names>KL</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>CI</given-names></name><name name-style="western"><surname>Satre</surname><given-names>DD</given-names></name></person-group><article-title>Alcohol and drug use, pain and psychiatric symptoms among adults seeking outpatient psychiatric treatment: latent class patterns and relationship to health status</article-title><source>J Psychoact Drugs</source><year>2018</year><volume>50</volume><fpage>43</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1080/02791072.2017.1401185</pub-id><pub-id pub-id-type="pmcid">PMC5933843</pub-id><pub-id pub-id-type="pmid">29199899</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Ramo DE, Bahorik AL, Delucchi KL, Campbell CI, Satre DD. Alcohol and drug use, pain and psychiatric symptoms among adults seeking outpatient psychiatric treatment: latent class patterns and relationship to health status. J Psychoact Drugs. 2018;50:43&#8211;53.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/02791072.2017.1401185</pub-id><pub-id pub-id-type="pmcid">PMC5933843</pub-id><pub-id pub-id-type="pmid">29199899</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Justice</surname><given-names>AC</given-names></name><name name-style="western"><surname>Dombrowski</surname><given-names>E</given-names></name><name name-style="western"><surname>Conigliaro</surname><given-names>J</given-names></name><name name-style="western"><surname>Fultz</surname><given-names>SL</given-names></name><name name-style="western"><surname>Gibson</surname><given-names>D</given-names></name><name name-style="western"><surname>Madenwald</surname><given-names>T</given-names></name><etal/></person-group><article-title>Veterans Aging Cohort Study (VACS): overview and description</article-title><source>Med Car</source><year>2006</year><volume>44</volume><fpage>S13</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1097/01.mlr.0000223741.02074.66</pub-id><pub-id pub-id-type="pmcid">PMC3049942</pub-id><pub-id pub-id-type="pmid">16849964</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Justice AC, Dombrowski E, Conigliaro J, Fultz SL, Gibson D, Madenwald T, et al. Veterans aging cohort study (VACS): overview and description. Med Car. 2006;44:S13&#8211;24.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/01.mlr.0000223741.02074.66</pub-id><pub-id pub-id-type="pmcid">PMC3049942</pub-id><pub-id pub-id-type="pmid">16849964</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Watkins</surname><given-names>KE</given-names></name><name name-style="western"><surname>Pincus</surname><given-names>HA</given-names></name><name name-style="western"><surname>Paddock</surname><given-names>S</given-names></name><name name-style="western"><surname>Smith</surname><given-names>B</given-names></name><name name-style="western"><surname>Woodroffe</surname><given-names>A</given-names></name><name name-style="western"><surname>Farmer</surname><given-names>C</given-names></name><etal/></person-group><article-title>Care for Veterans with Mental and Substance Use disorders: good performance, but Room to improve on many measures</article-title><source>Health Aff (Millwood)</source><year>2011</year><volume>30</volume><fpage>2194</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1377/hlthaff.2011.0509</pub-id><pub-id pub-id-type="pmid">22012967</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Watkins KE, Pincus HA, Paddock S, Smith B, Woodroffe A, Farmer C, et al. Care for veterans with mental and substance use disorders: good performance, but room to improve on many measures. Health Aff (Millwood). 2011;30:2194&#8211;203.<pub-id pub-id-type="pmid">22012967</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1377/hlthaff.2011.0509</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oliva</surname><given-names>EM</given-names></name><name name-style="western"><surname>Harris</surname><given-names>AHS</given-names></name><name name-style="western"><surname>Trafton</surname><given-names>JA</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>AJ</given-names></name></person-group><article-title>Receipt of opioid agonist treatment in the Veterans Health Administration: facility and patient factors</article-title><source>Drug Alcohol Depend</source><year>2012</year><volume>122</volume><fpage>241</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.drugalcdep.2011.10.004</pub-id><pub-id pub-id-type="pmid">22115887</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Oliva EM, Harris AHS, Trafton JA, Gordon AJ. Receipt of opioid agonist treatment in the Veterans Health Administration: facility and patient factors. Drug Alcohol Depend. 2012;122:241&#8211;6.<pub-id pub-id-type="pmid">22115887</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drugalcdep.2011.10.004</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oliva</surname><given-names>EM</given-names></name><name name-style="western"><surname>Trafton</surname><given-names>JA</given-names></name><name name-style="western"><surname>Harris</surname><given-names>AHS</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>AJ</given-names></name></person-group><article-title>Trends in Opioid Agonist Therapy in the Veterans Health Administration: is supply keeping up with demand?</article-title><source>Am J Drug Alcohol Abuse</source><year>2013</year><volume>39</volume><fpage>103</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.3109/00952990.2012.741167</pub-id><pub-id pub-id-type="pmid">23421571</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Oliva EM, Trafton JA, Harris AHS, Gordon AJ. Trends in opioid agonist therapy in the Veterans Health Administration: is supply keeping up with demand? Am J Drug Alcohol Abuse. 2013;39:103&#8211;7.<pub-id pub-id-type="pmid">23421571</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3109/00952990.2012.741167</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carr</surname><given-names>MM</given-names></name><name name-style="western"><surname>Wolkowicz</surname><given-names>NR</given-names></name><name name-style="western"><surname>Cave</surname><given-names>S</given-names></name><name name-style="western"><surname>Martino</surname><given-names>S</given-names></name><name name-style="western"><surname>Masheb</surname><given-names>R</given-names></name><name name-style="western"><surname>Midboe</surname><given-names>AM</given-names></name></person-group><article-title>Weight change in a national cohort of U.S. Military Veterans engaged in medication treatment for opioid use disorder</article-title><source>J Psychiatr Res</source><year>2023</year><volume>168</volume><fpage>204</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/j.jpsychires.2023.10.012</pub-id><pub-id pub-id-type="pmid">37918033</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Carr MM, Wolkowicz NR, Cave S, Martino S, Masheb R, Midboe AM. Weight change in a national cohort of U.S. Military Veterans engaged in medication treatment for opioid use disorder. J Psychiatr Res. 2023;168:204&#8211;12.<pub-id pub-id-type="pmid">37918033</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jpsychires.2023.10.012</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wyse</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Dobscha</surname><given-names>SK</given-names></name><name name-style="western"><surname>Morasco</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Tiffany</surname><given-names>E</given-names></name><name name-style="western"><surname>Drexler</surname><given-names>K</given-names></name><etal/></person-group><article-title>Medications for opioid use disorder in the Department of Veterans affairs (VA) health care system: historical perspective, lessons learned, and next steps</article-title><source>Subst Abus</source><year>2018</year><volume>39</volume><fpage>139</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1080/08897077.2018.1452327</pub-id><pub-id pub-id-type="pmid">29595375</pub-id><pub-id pub-id-type="pmcid">PMC8054831</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Wyse JJ, Gordon AJ, Dobscha SK, Morasco BJ, Tiffany E, Drexler K, et al. Medications for opioid use disorder in the Department of Veterans Affairs (VA) health care system: historical perspective, lessons learned, and next steps. Subst Abus. 2018;39:139&#8211;44.<pub-id pub-id-type="pmid">29595375</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/08897077.2018.1452327</pub-id><pub-id pub-id-type="pmcid">PMC8054831</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manhapra</surname><given-names>A</given-names></name><name name-style="western"><surname>Agbese</surname><given-names>E</given-names></name><name name-style="western"><surname>Leslie</surname><given-names>DL</given-names></name><name name-style="western"><surname>Rosenheck</surname><given-names>RA</given-names></name></person-group><article-title>Three-year Retention in Buprenorphine Treatment for Opioid Use Disorder among privately insured adults</article-title><source>Psychiatric Serv</source><year>2018</year><volume>69</volume><fpage>768</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1176/appi.ps.201700363</pub-id><pub-id pub-id-type="pmid">29656707</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Manhapra A, Agbese E, Leslie DL, Rosenheck RA. Three-year retention in buprenorphine treatment for opioid use disorder among privately insured adults. Psychiatric Serv. 2018;69:768&#8211;76.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1176/appi.ps.201700363</pub-id><pub-id pub-id-type="pmid">29656707</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saloner</surname><given-names>B</given-names></name><name name-style="western"><surname>Daubresse</surname><given-names>M</given-names></name><name name-style="western"><surname>Alexander</surname><given-names>GC</given-names></name></person-group><article-title>Patterns of Buprenorphine-Naloxone Treatment for Opioid Use Disorder in a Multi-state Population</article-title><source>Med Care</source><year>2017</year><volume>55</volume><fpage>669</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1097/MLR.0000000000000727</pub-id><pub-id pub-id-type="pmid">28410339</pub-id><pub-id pub-id-type="pmcid">PMC6528471</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Saloner B, Daubresse M, Alexander GC. Patterns of Buprenorphine-Naloxone treatment for opioid use disorder in a multi-state population. Med Care. 2017;55:669&#8211;76.<pub-id pub-id-type="pmid">28410339</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MLR.0000000000000727</pub-id><pub-id pub-id-type="pmcid">PMC6528471</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oldfield</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Mcginnis</surname><given-names>KA</given-names></name><name name-style="western"><surname>Edelman</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Williams</surname><given-names>EC</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Akg&#252;n</surname><given-names>K</given-names></name><etal/></person-group><article-title>Predictors of initiation of and retention on medications for alcohol use disorder among people living with and without HIV</article-title><source>J Subst Abuse Treat</source><year>2020</year><volume>109</volume><fpage>14</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1016/j.jsat.2019.11.002</pub-id><pub-id pub-id-type="pmid">31856946</pub-id><pub-id pub-id-type="pmcid">PMC6982467</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Oldfield BJ, Mcginnis KA, Edelman EJ, Williams EC, Gordon AJ, Akg&#252;n K, et al. Predictors of initiation of and retention on medications for alcohol use disorder among people living with and without HIV. J Subst Abuse Treat. 2020;109:14&#8211;22.<pub-id pub-id-type="pmid">31856946</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jsat.2019.11.002</pub-id><pub-id pub-id-type="pmcid">PMC6982467</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><mixed-citation publication-type="other">McGinnis KA, Fiellin DA, Skanderson M, Hser Y, Lucas GM, Justice AC et al. Opioid use trajectory groups and changes in a physical health biomarker among HIV-positive and uninfected patients receiving opioid agonist treatment. Drug Alcohol Depend. 2019;204.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drugalcdep.2019.06.014</pub-id><pub-id pub-id-type="pmcid">PMC6993986</pub-id><pub-id pub-id-type="pmid">31546119</pub-id></mixed-citation></ref><ref id="CR42"><label>42.</label><mixed-citation publication-type="other">Kennedy AJ, McGinnis KA, Merlin JS, Edelman EJ, Gordon AJ, Korthuis PT et al. Impact of intensity of behavioral treatment, with or without medication treatment, for opioid use disorder on HIV outcomes in persons with HIV. J Subst Abuse Treat. 2022;132.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jsat.2021.108509</pub-id><pub-id pub-id-type="pmcid">PMC8628025</pub-id><pub-id pub-id-type="pmid">34130128</pub-id></mixed-citation></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goulet</surname><given-names>JL</given-names></name><name name-style="western"><surname>Brandt</surname><given-names>C</given-names></name><name name-style="western"><surname>Crystal</surname><given-names>S</given-names></name><name name-style="western"><surname>Fiellin</surname><given-names>DA</given-names></name><name name-style="western"><surname>Gibert</surname><given-names>C</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>AJ</given-names></name><etal/></person-group><article-title>Agreement between Electronic Medical Record-based and Self-Administered Pain Numeric Rating Scale: clinical and Research implications</article-title><source>Med Care</source><year>2013</year><volume>51</volume><fpage>245</fpage><pub-id pub-id-type="doi">10.1097/MLR.0b013e318277f1ad</pub-id><pub-id pub-id-type="pmid">23222528</pub-id><pub-id pub-id-type="pmcid">PMC3572341</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Goulet JL, Brandt C, Crystal S, Fiellin DA, Gibert C, Gordon AJ, et al. Agreement between electronic medical record-based and self-administered pain numeric rating scale: clinical and research implications. Med Care. 2013;51:245.<pub-id pub-id-type="pmid">23222528</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MLR.0b013e318277f1ad</pub-id><pub-id pub-id-type="pmcid">PMC3572341</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>G</given-names></name><name name-style="western"><surname>Jensen</surname><given-names>MP</given-names></name><name name-style="western"><surname>Thornby</surname><given-names>JI</given-names></name><name name-style="western"><surname>Rintala</surname><given-names>DH</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>KO</given-names></name></person-group><article-title>Categorizing pain in patients seen in a veterans health administration hospital: Pain as the fifth vital sign</article-title><source>Psychol Serv</source><year>2008</year><volume>5</volume><fpage>239</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1037/1541-1559.5.3.239</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Tan G, Jensen MP, Thornby JI, Rintala DH, Anderson KO. Categorizing pain in patients seen in a veterans health administration hospital: Pain as the fifth vital sign. Psychol Serv. 2008;5:239&#8211;50.</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Womack</surname><given-names>JA</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>TE</given-names></name><name name-style="western"><surname>Bathulapalli</surname><given-names>H</given-names></name><name name-style="western"><surname>Akg&#252;n</surname><given-names>KM</given-names></name><name name-style="western"><surname>Gibert</surname><given-names>C</given-names></name><name name-style="western"><surname>Kunisaki</surname><given-names>KM</given-names></name><etal/></person-group><article-title>Sleep disturbance among HIV infected and uninfected veterans</article-title><source>J Acquir Immune Defic Syndr</source><year>2017</year><volume>74</volume><fpage>e117</fpage><pub-id pub-id-type="doi">10.1097/QAI.0000000000001264</pub-id><pub-id pub-id-type="pmid">27906767</pub-id><pub-id pub-id-type="pmcid">PMC5326673</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Womack JA, Murphy TE, Bathulapalli H, Akg&#252;n KM, Gibert C, Kunisaki KM, et al. Sleep disturbance among HIV infected and uninfected veterans. J Acquir Immune Defic Syndr. 2017;74:e117.<pub-id pub-id-type="pmid">27906767</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/QAI.0000000000001264</pub-id><pub-id pub-id-type="pmcid">PMC5326673</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mayhew</surname><given-names>M</given-names></name><name name-style="western"><surname>DeBar</surname><given-names>L</given-names></name><name name-style="western"><surname>Deyo</surname><given-names>R</given-names></name><name name-style="western"><surname>Kerns</surname><given-names>R</given-names></name><name name-style="western"><surname>Goulet</surname><given-names>J</given-names></name></person-group><article-title>Development and Assessment of a crosswalk between ICD-9- CM and ICD-10-CM to identify patients with Common Pain conditions</article-title><source>Physiol Behav</source><year>2017</year><volume>176</volume><fpage>139</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">31129316</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jpain.2019.05.006</pub-id><pub-id pub-id-type="pmcid">PMC6874733</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Mayhew M, DeBar L, Deyo R, Kerns R, Goulet J. Development and assessment of a crosswalk between ICD-9-CM and ICD-10-CM to identify patients with common pain conditions. Physiol Behav. 2017;176:139&#8211;48.<pub-id pub-id-type="pmid">31129316</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jpain.2019.05.006</pub-id><pub-id pub-id-type="pmcid">PMC6874733</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><mixed-citation publication-type="other">Nagin DS. Group-based modeling of development. Harvard; 2005.</mixed-citation></ref><ref id="CR48"><label>48.</label><mixed-citation publication-type="other">Mancher M,&#160;Leshner AI, editors. Medications for opioid use disorder save lives. Washington, D.C.: National Academies; 2019.<pub-id pub-id-type="pmid">30896911</pub-id></mixed-citation></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hutchinson</surname><given-names>E</given-names></name><name name-style="western"><surname>Catlin</surname><given-names>M</given-names></name><name name-style="western"><surname>Andrilla</surname><given-names>CHA</given-names></name><name name-style="western"><surname>Baldwin</surname><given-names>LM</given-names></name><name name-style="western"><surname>Rosenblatt</surname><given-names>RA</given-names></name></person-group><article-title>Barriers to primary care physicians prescribing buprenorphine</article-title><source>Ann Fam Med</source><year>2014</year><volume>12</volume><fpage>128</fpage><lpage>33</lpage><pub-id pub-id-type="doi">10.1370/afm.1595</pub-id><pub-id pub-id-type="pmid">24615308</pub-id><pub-id pub-id-type="pmcid">PMC3948759</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Hutchinson E, Catlin M, Andrilla CHA, Baldwin LM, Rosenblatt RA. Barriers to primary care physicians prescribing buprenorphine. Ann Fam Med. 2014;12:128&#8211;33.<pub-id pub-id-type="pmid">24615308</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1370/afm.1595</pub-id><pub-id pub-id-type="pmcid">PMC3948759</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andrilla</surname><given-names>CHA</given-names></name><name name-style="western"><surname>Moore</surname><given-names>TE</given-names></name><name name-style="western"><surname>Patterson</surname><given-names>DG</given-names></name></person-group><article-title>Overcoming barriers to Prescribing Buprenorphine for the treatment of opioid use disorder: recommendations from Rural Physicians</article-title><source>J Rural Health</source><year>2019</year><volume>35</volume><fpage>113</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1111/jrh.12328</pub-id><pub-id pub-id-type="pmid">30339720</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Andrilla CHA, Moore TE, Patterson DG. Overcoming barriers to prescribing buprenorphine for the treatment of opioid use disorder: recommendations from rural physicians. J Rural Health. 2019;35:113&#8211;21.<pub-id pub-id-type="pmid">30339720</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jrh.12328</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><mixed-citation publication-type="other">Samples H, Williams AR, Olfson M, Crystal S. Risk factors for discontinuation of buprenorphine treatment for opioid use disorders in a multi-state sample of Medicaid enrollees. J Subst Abuse Treat. 2018;95.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jsat.2018.09.001</pub-id><pub-id pub-id-type="pmcid">PMC6354252</pub-id><pub-id pub-id-type="pmid">30352671</pub-id></mixed-citation></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsui</surname><given-names>JI</given-names></name><name name-style="western"><surname>Mayfield</surname><given-names>J</given-names></name><name name-style="western"><surname>Speaker</surname><given-names>EC</given-names></name><name name-style="western"><surname>Yakup</surname><given-names>S</given-names></name><name name-style="western"><surname>Ries</surname><given-names>R</given-names></name><name name-style="western"><surname>Funai</surname><given-names>H</given-names></name><etal/></person-group><article-title>Association between methamphetamine use and retention among patients with opioid use disorders treated with buprenorphine</article-title><source>J Subst Abuse Treat</source><year>2020</year><volume>109</volume><fpage>80</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1016/j.jsat.2019.10.005</pub-id><pub-id pub-id-type="pmid">31810594</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Tsui JI, Mayfield J, Speaker EC, Yakup S, Ries R, Funai H, et al. Association between methamphetamine use and retention among patients with opioid use disorders treated with buprenorphine. J Subst Abuse Treat. 2020;109:80&#8211;5.<pub-id pub-id-type="pmid">31810594</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jsat.2019.10.005</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schuman-Olivier</surname><given-names>Z</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>RD</given-names></name><name name-style="western"><surname>Hoeppner</surname><given-names>BB</given-names></name><name name-style="western"><surname>Borodovsky</surname><given-names>J</given-names></name><name name-style="western"><surname>Albanese</surname><given-names>MJ</given-names></name></person-group><article-title>Emerging adult age status predicts poor buprenorphine treatment retention</article-title><source>J Subst Abuse Treat</source><year>2014</year><volume>47</volume><fpage>202</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/j.jsat.2014.04.006</pub-id><pub-id pub-id-type="pmid">24953168</pub-id><pub-id pub-id-type="pmcid">PMC4180514</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Schuman-Olivier Z, Weiss RD, Hoeppner BB, Borodovsky J, Albanese MJ. Emerging adult age status predicts poor buprenorphine treatment retention. J Subst Abuse Treat. 2014;47:202&#8211;12.<pub-id pub-id-type="pmid">24953168</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jsat.2014.04.006</pub-id><pub-id pub-id-type="pmcid">PMC4180514</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hser</surname><given-names>YI</given-names></name><name name-style="western"><surname>Mooney</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Saxon</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Miotto</surname><given-names>K</given-names></name><name name-style="western"><surname>Bell</surname><given-names>DS</given-names></name><name name-style="western"><surname>Huang</surname><given-names>D</given-names></name></person-group><article-title>Chronic pain among patients with opioid use disorder: results from electronic health records data</article-title><source>J Subst Abuse Treat</source><year>2017</year><volume>77</volume><fpage>26</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1016/j.jsat.2017.03.006</pub-id><pub-id pub-id-type="pmid">28476267</pub-id><pub-id pub-id-type="pmcid">PMC5424616</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Hser YI, Mooney LJ, Saxon AJ, Miotto K, Bell DS, Huang D. Chronic pain among patients with opioid use disorder: results from electronic health records data. J Subst Abuse Treat. 2017;77:26&#8211;30.<pub-id pub-id-type="pmid">28476267</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jsat.2017.03.006</pub-id><pub-id pub-id-type="pmcid">PMC5424616</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ker</surname><given-names>S</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>J</given-names></name><name name-style="western"><surname>Balani</surname><given-names>A</given-names></name><name name-style="western"><surname>Mukherjee</surname><given-names>SS</given-names></name><name name-style="western"><surname>Rush</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Khan</surname><given-names>M</given-names></name><etal/></person-group><article-title>Factors that affect patient attrition in buprenorphine treatment for opioid use disorder: a retrospective real-world study using electronic health records</article-title><source>Neuropsychiatr Dis Treat</source><year>2021</year><volume>17</volume><fpage>3229</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.2147/NDT.S331442</pub-id><pub-id pub-id-type="pmid">34737569</pub-id><pub-id pub-id-type="pmcid">PMC8560173</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Ker S, Hsu J, Balani A, Mukherjee SS, Rush AJ, Khan M, et al. Factors that affect patient attrition in buprenorphine treatment for opioid use disorder: a retrospective real-world study using electronic health records. Neuropsychiatr Dis Treat. 2021;17:3229&#8211;44.<pub-id pub-id-type="pmid">34737569</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/NDT.S331442</pub-id><pub-id pub-id-type="pmcid">PMC8560173</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><mixed-citation publication-type="other">Dunphy C, Peterson C, Zhang K, Jones CM. Do out-of-pocket costs influence retention and adherence to medications for opioid use disorder? Drug Alcohol Depend. 2021;225.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drugalcdep.2021.108784</pub-id><pub-id pub-id-type="pmcid">PMC8314254</pub-id><pub-id pub-id-type="pmid">34049104</pub-id></mixed-citation></ref><ref id="CR57"><label>57.</label><mixed-citation publication-type="other">Gertner AK, Clare HM, Powell BJ, Gilbert AR, Jones HE, Silberman P et al. A mixed methods study of provider factors in buprenorphine treatment retention. Int J Drug Policy. 2022;105.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drugpo.2022.103715</pub-id><pub-id pub-id-type="pmcid">PMC9246997</pub-id><pub-id pub-id-type="pmid">35533634</pub-id></mixed-citation></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gordon</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Lo-Ciganic</surname><given-names>WH</given-names></name><name name-style="western"><surname>Cochran</surname><given-names>G</given-names></name><name name-style="western"><surname>Gellad</surname><given-names>WF</given-names></name><name name-style="western"><surname>Cathers</surname><given-names>T</given-names></name><name name-style="western"><surname>Kelley</surname><given-names>D</given-names></name><etal/></person-group><article-title>Patterns and quality of Buprenorphine Opioid Agonist Treatment in a large Medicaid Program</article-title><source>J Addict Med</source><year>2015</year><volume>9</volume><fpage>470</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1097/ADM.0000000000000164</pub-id><pub-id pub-id-type="pmid">26517324</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Gordon AJ, Lo-Ciganic WH, Cochran G, Gellad WF, Cathers T, Kelley D, et al. Patterns and quality of buprenorphine opioid agonist treatment in a large medicaid program. J Addict Med. 2015;9:470&#8211;7.<pub-id pub-id-type="pmid">26517324</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/ADM.0000000000000164</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Manhapra</surname><given-names>A</given-names></name><name name-style="western"><surname>Quinones</surname><given-names>L</given-names></name><name name-style="western"><surname>Rosenheck</surname><given-names>R</given-names></name></person-group><article-title>Characteristics of veterans receiving buprenorphine vs. methadone for opioid use disorder nationally in the Veterans Health Administration</article-title><source>Drug Alcohol Depend</source><year>2016</year><volume>160</volume><fpage>82</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.drugalcdep.2015.12.035</pub-id><pub-id pub-id-type="pmid">26804898</pub-id><pub-id pub-id-type="pmcid">PMC4767635</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Manhapra A, Quinones L, Rosenheck R. Characteristics of veterans receiving buprenorphine vs. methadone for opioid use disorder nationally in the Veterans Health Administration. Drug Alcohol Depend. 2016;160:82&#8211;9.<pub-id pub-id-type="pmid">26804898</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drugalcdep.2015.12.035</pub-id><pub-id pub-id-type="pmcid">PMC4767635</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lagisetty</surname><given-names>P</given-names></name><name name-style="western"><surname>Ross</surname><given-names>R</given-names></name><name name-style="western"><surname>Bohnert</surname><given-names>A</given-names></name><name name-style="western"><surname>Clay</surname><given-names>M</given-names></name><name name-style="western"><surname>Maust</surname><given-names>D</given-names></name></person-group><article-title>Buprenorphine Treatment divide by Race/Ethnicity and payment</article-title><source>JAMA Psychiatry</source><year>2019</year><volume>76</volume><fpage>979</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1001/jamapsychiatry.2019.0876</pub-id><pub-id pub-id-type="pmid">31066881</pub-id><pub-id pub-id-type="pmcid">PMC6506898</pub-id></element-citation><mixed-citation id="mc-CR60" publication-type="journal">Lagisetty P, Ross R, Bohnert A, Clay M, Maust D. Buprenorphine treatment divide by race/ethnicity and payment. JAMA Psychiatry. 2019;76:979&#8211;80.<pub-id pub-id-type="pmid">31066881</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jamapsychiatry.2019.0876</pub-id><pub-id pub-id-type="pmcid">PMC6506898</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weinstein</surname><given-names>ZM</given-names></name><name name-style="western"><surname>Kim</surname><given-names>HW</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>DM</given-names></name><name name-style="western"><surname>Quinn</surname><given-names>E</given-names></name><name name-style="western"><surname>Hui</surname><given-names>D</given-names></name><name name-style="western"><surname>Labelle</surname><given-names>CT</given-names></name><etal/></person-group><article-title>Long-term retention in Office based opioid treatment with buprenorphine</article-title><source>J Subst Abuse Treat</source><year>2017</year><volume>74</volume><fpage>65</fpage><lpage>70</lpage><pub-id pub-id-type="doi">10.1016/j.jsat.2016.12.010</pub-id><pub-id pub-id-type="pmid">28132702</pub-id><pub-id pub-id-type="pmcid">PMC5312773</pub-id></element-citation><mixed-citation id="mc-CR61" publication-type="journal">Weinstein ZM, Kim HW, Cheng DM, Quinn E, Hui D, Labelle CT, et al. Long-term retention in office ased opioid treatment with buprenorphine. J Subst Abuse Treat. 2017;74:65&#8211;70.<pub-id pub-id-type="pmid">28132702</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jsat.2016.12.010</pub-id><pub-id pub-id-type="pmcid">PMC5312773</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><mixed-citation publication-type="other">Bailey SR, Lucas JA, Angier H, Cantone RE, Fleishman J, Garvey B et al. Associations of retention on buprenorphine for opioid use disorder with patient characteristics and models of care in the primary care setting. J Subst Abuse Treat. 2021;131.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jsat.2021.108548</pub-id><pub-id pub-id-type="pmcid">PMC8664960</pub-id><pub-id pub-id-type="pmid">34244013</pub-id></mixed-citation></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ochalek</surname><given-names>T</given-names></name><name name-style="western"><surname>Cumpston</surname><given-names>K</given-names></name><name name-style="western"><surname>Wills</surname><given-names>B</given-names></name><name name-style="western"><surname>Gal</surname><given-names>T</given-names></name><name name-style="western"><surname>Moeller</surname><given-names>F</given-names></name></person-group><article-title>Nonfatal opioid overdoses at an urban Emergency Department during the COVID-19 pandemic</article-title><source>JAMA</source><year>2020</year><volume>323</volume><fpage>1891</fpage><lpage>2</lpage><pub-id pub-id-type="pmid">32945832</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2020.17477</pub-id><pub-id pub-id-type="pmcid">PMC7501586</pub-id></element-citation><mixed-citation id="mc-CR63" publication-type="journal">Ochalek T, Cumpston K, Wills B, Gal T, Moeller F. Nonfatal opioid overdoses at an urban emergency department during the COVID-19 pandemic. JAMA. 2020;323:1891&#8211;2.<pub-id pub-id-type="pmid">32945832</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2020.17477</pub-id><pub-id pub-id-type="pmcid">PMC7501586</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alsebaa</surname><given-names>F</given-names></name><name name-style="western"><surname>Akbar</surname><given-names>H</given-names></name></person-group><article-title>Barriers to accessing opioid use disorder treatment in older adults</article-title><source>Am J Geriatric Psychiatry</source><year>2023</year><volume>31</volume><fpage>S69</fpage><pub-id pub-id-type="doi">10.1016/j.jagp.2022.12.230</pub-id></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Alsebaa F, Akbar H. Barriers to accessing opioid use disorder treatment in older adults. Am J Geriatric Psychiatry. 2023;31:S69.</mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><mixed-citation publication-type="other">Alexandridis AA, Dasgupta N, Ringwalt CL, Rosamond WD, Chelminski PR, Marshall SW. Association between opioid analgesic therapy and initiation of buprenorphine management: an analysis of prescription drug monitoring program data. PLoS ONE. 2020;15.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0227350</pub-id><pub-id pub-id-type="pmcid">PMC6953786</pub-id><pub-id pub-id-type="pmid">31923197</pub-id></mixed-citation></ref><ref id="CR66"><label>66.</label><mixed-citation publication-type="other">Rowe CL, Santos GM, Kornbluh W, Bhardwaj S, Faul M, Coffin PO. Using ICD-10-CM codes to detect illicit substance use: a comparison with retrospective self-report. Drug Alcohol Depend. 2021;221.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.drugalcdep.2021.108537</pub-id><pub-id pub-id-type="pmcid">PMC11008535</pub-id><pub-id pub-id-type="pmid">33621806</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>